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Background: Iron induced heart failure is the commonest cause of death in thalssaemia major. 
The cardiomyopathy is reversible when treated early, but once symptomatic heart failure occurs, 
the outlook is poor. A recent technique using magnetic resonance myocardial T2* (T2 star) has 
been validated for the assessment of early myocardial iron deposition. Worldwide however, 
transthoracic echocardiography is the mainstay of assessment for these patients. Conventional 
echo parameters are poor at identifying those with cardiac iron loading who are at risk of cardiac 
failure, only becoming abnormal once significant iron loading has occurred. Newer techniques 
involving tissue Doppler imaging (TDI) have been promising. Our aim was to explore the role 
of these techniques and that of brain natriuretic peptide (BNP), a biomarker released in heart 
failure, in the management of Thalassaemia major patients. 
Methods/Results: 167 patients with thalassaemia major were screened with cardiac T2* MRI to 
quantify iron loading. Those with severe cardiac iron, T2* <8ms, (n=15) were treated with both 
desferrioxamine and deferiprone chelation. Those with mild to moderate cardiac iron, T2* 8-
20ms, (n=65) were randomised to desferrioxamine plus either deferiprone or placebo. Both 
groups were treated for 12 months. At baseline, 6 and 12 months all those in the combination 
therapy trial and in the severe group were assessed with T2*, full transthoracic 
echocardiography including TDI and BNP levels. BNP only became abnormal in those with 
obvious clinical heart failure. TDI systolic velocities in the septum and RV were significantly 
lower in those with severe cardiac iron and improved over 12 months, correlating with an 
improvement in T2*. 
Conclusion: In thalassaemia patients, BNP is unhelpful in assessing cardiac iron status. Systolic 
tissue velocities can give an indication as to an individuals cardiac iron status and could help to 
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CHAPTER 1 SUMMARY AND OBJECTIVES 
 
 
Thalassaemia major is an inherited anaemia and is fatal without recurrent blood transfusions 
which are required to allow normal development. Although a necessity, blood transfusions cause 
cardiac iron loading and result in cardiac failure, the major cause of death in this patient group. 
Iron-induced heart failure is a potentially reversible condition provided it is detected early and 
appropriate intensification of iron-chelation treatment is instituted in time. The recent 
development of T2* cardiac MRI allows quantification of iron status and assessment of 
significant cardiac iron at an early stage. This has been a major advance, allowing management 
of myocardial iron deposition in a way which has not previously been possible. Worldwide, due 
to cost and availability limitations, transthoracic echo (TTE) is the mainstay of cardiac 
monitoring in this patient group. Early work with newer echo techniques such as tissue Doppler 
imaging (TDI) has been promising. This thesis explores the role of these newer techniques 
including strain, strain rate and longitudinal motion (tissue tracking) to examine if they can be 
used to identify patients with significant cardiac iron loading and therefore at risk of cardiac 
decompensation. The role of these parameters for monitoring progression of disease or effects of 
intensive chelation treatment will be investigated. The thesis also explores the role of brain 
natriuretic peptide to see if this biomarker may have a role in assessment and monitoring of 
patients with transfusion dependant thalassaemia major. 
 
The relationship between a number of conventional and tissue Doppler derived echo parameters 
and cardiac T2* are defined. The change in these echo parameters following intensive treatment 
is defined in groups with both severe cardiac iron and mild to moderate cardiac iron. The use of 
BNP estimates is explored and defined in this group of patients. The role of BNP pre and post 
blood transfusion is also explored. 
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CHAPTER 2: THALASSAEMIA MAJOR 
 
2.1 HISTORY, DISTRIBUTION AND PREVALENCE 
The thalassaemias are the single most common monogenic disorders worldwide. Initially 
described in a series of infants by Thomas Cooley in 1925. In 1936 Whipple and Bradford 
introduced the term thalassaemia as the patients seemed to be predominantly of Mediterranean 
origin. Thalassaemia occurs in a wide geographic area from the Mediterranean, parts of north 
and west Africa, through the middle east and Indian subcontinent to south east Asia (Figure 2.1). 
Inheritance is an autosomal recessive pattern, asymptomatic heterozygotes having a 25% chance 
of an affected child. The heterozygote carrier frequency varies from 3 to 30%. Although the 
thalassaemia gene is absent in Northern Europeans, it is now present in every industrialised 
nation in the world due to migration from high prevalence areas. In the UK in 1999 there were 
1049 patients on the Thalassaemia Register (1) and by 2003 the number was 1089 of which 856 
were alive (2) and approximately half resident in north London attending the Whittington 
Hospital, a national thalassaemia referral centre. A study of Asian children in northwest London 
showed 4% were heterozygous carriers for beta thalassaemia (3). Worldwide, there are some 94 
million people heterozygote for thalassaemia and up to 60,000 homozygote births per year (4). 
Beta thalassaemia can also occur sporadically in every racial group (5;6). Improving social 
conditions and medical interventions worldwide have allowed children with thalassaemia to 
survive long enough to require treatment for longer term complications. This makes the 
management of the disease increasingly important, both where the disease is particularly 







Figure 2.1  Global Distribution of Thalassaemia Major 
 
 
2.2 NATURAL HISTORY OF THALASSAEMIA 
Commonly the beta globin chain production is absent (beta-0 thalassaemia) or reduced (beta + 
thalassaemia). This results in excess production of alpha globin chains which are unstable, 
precipitate within the red blood cell and lead to its destruction within the bone marrow and 
spleen. The resultant severe anaemia is compounded by premature red cell destruction within the 
spleen and stimulates ineffective erythropoiesis leading to marrow expansion and bony 
deformities. In severe untreated beta thalassaemia, erythropoiesis may be increased by a factor 
of up to 10, more than 95 percent of which may be ineffective. The severe ineffective 
erythropoiesis results in marrow expansion to as much as 30 times the normal level. The 
anaemia is exacerbated by an increased plasma volume due to shunting through expanded 
marrow and splenomegaly. Clinically, thalassaemia major (TM) usually becomes apparent 
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during the first year of life as the switch from foetal haemoglobin (α2γ2) to adult haemoglobin 
(α2β2) occurs, and the anaemia progressively worsens. TM is at the severe end of the spectrum of 
homozygous β-thalassaemia and requires regular blood transfusions to prevent death in infancy 
due to anaemia (7). Regular blood transfusions switch off the erythropoietic drive, allowing 
thalassaemic children to grow and develop normally and are required to prolong life, ensure 
normal growth and development and avoid complications of chronic anaemia (7;8). However, in 
treated patients the combination of transfusional iron (200-250mg per unit of blood), and an 
inappropriate increase in intestinal absorption (9), leads to an inexorable accumulation of iron in 
the body tissues (10). Eventually, extensive iron-induced injury develops in the heart (10-12), 
liver (10;12;13), pancreas (10;14) and endocrine organs(10;12;15). 
 
Regular transfusion to maintain a mean haemoglobin in the normal range became standard 
treatment in the 1960s (16). This results in good quality of life in the short term, but leads to 
death from transfusional iron overload between 12 and 24 years of age (2;16). With or without 
blood transfusion, patients require treatment to prevent iron overload, the consequences of 
which are fatal. Long term survival is determined by the degree of cardiac iron loading (17;18). 
If transfusions are not received the increased iron absorption amounts to an iron burden of 2-5g 
per year (19;20). Regular blood transfusions may double the rate of iron accumulation. Although 
the clinical manifestations of iron overload do not usually appear until the second decade of life, 
evidence from liver biopsies indicate that the damaging effects of iron accumulate much earlier 
than this. After approximately one year of transfusions, iron begins to be deposited in 
parenchymal tissues and may cause toxicity (13). The effects of untreated progressive cardiac 
iron overload have been previously documented by Engle (21). Around the age of 10 years, the 
heart size increases and left ventricular hypertrophy develops on the ECG(21) Clinically 
apparent, although symptomatically silent the cardiac effects of iron overload begin with the 
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accumulation of 20 g of iron, usually after the age of 10 years, in a regularly transfused child 
maintained with a pre-transfusion haemoglobin of 9 to 10 g/dl, unless adequate chelation has 
been prescribed and taken (22). Within 10 years of regular transfusions without chelation 
therapy cardiac symptoms are reported (23) and may be aggravated by myocarditis (24) or 
pulmonary hypertension (25;26). At 10 years, one third of patients have 1st degree heart block, 
progressing to either 3rd degree heart block or left or right bundle branch block as heart failure 
develops. Pericarditis commonly occurs over the age of 11. Congestive cardiac failure secondary 
to an iron induced cardiomyopathy develops at a mean age of 16 years, with survival over the 
age of 20 years being rare(21). Atrial arrhythmias occur in over half the patients as do frequent 
ventricular ectopics. Arrhythmias correlate with the extent of iron deposition in the atrial tissue 
(11). Sustained runs of ventricular tachycardia occur in a minority(21). Once overt clinical heart 
failure develops mean survival is 3 months (21) and presentation in NYHA class 4 heart failure 
has a 50% acute mortality (JMW observations, unpublished data).  
 
2.3 IRON INDUCED DAMAGE AND CARDIOMYOPATHY 
The human body has no mechanism for excreting excess iron, which is stored as crystalline iron 
oxide within ferritin and haemosiderin in the body. At normal body iron levels, plasma iron is 
bound to transferrin, preventing catalytic activity and free radical production (27-29). The 
combination of increased gastrointestinal iron absorption and iron from red cell breakdown in 
the reticuloendothelial system saturates this iron binding capacity and this results in the 
emergence of non-transferrin bound iron (NTBI) (30). NTBI is more toxic than bound iron and 
promotes hydroxyl free radical formation (31) resulting in damage to membrane lipids and 
proteins. NTBI is taken up more readily by cardiac myocytes than transferrin bound iron (32). 
Whereas transferrin bound iron uptake is reduced by the down regulation of transferrin 
receptors, NTBI uptake is increased in the presence of high levels of tissue iron (33). In the 
heart, free intracellular iron results in impaired Na-K-ATPase activity (34), increased lysosomal 
 14
fragility (35) and impaired mitochondrial respiratory chain activity (36), and is manifest 
clinically as heart failure(37). Desferrioxamine (Desferal, Deferoxamine) binds iron, making it 
inactive metabolically and preventing the effects of free radical formation (32;38), (39), as does 
Deferiprone (L1). 
 
Iron deposition in the heart follows a characteristic pattern (11), with the left ventricular wall 
containing the most iron(40;41). Iron deposition in the left ventricular wall is non uniform, with 
the epicardial layer containing the most, the endocardium containing a moderate and the 
intermediate layer containing the least amount of iron (Figure 2.2). The degree of cardiac 
dysfunction depends on the quantity of iron deposited in individual myocardial fibres and the 
number of fibres affected. The relatively mild degree of fibrosis in most autopsy studies 
suggests that even when advanced, the cardiomyopathy is potentially reversible (11;42), and this 
has been demonstrated on numerous occasions (43-45).  
 
 
Figure 2.2 The distribution of iron in the heart can be seen from this short axis MR image. 
The arrow points to the left ventricular epicardium, where there is the most iron, which 
appears as a black rim. 
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2.4 CURRENT TREATMENTS  OF THALASSAEMIA MAJOR 
The current treatment of Thalassaemia major patients consists of regular blood transfusions, in 
the order of 2 units every 2-4 weeks, and iron chelation therapy. The decision to initiate regular 
transfusions may be a difficult one and is based on the severity of the signs of anaemia e.g. 
growth failure. The aims of transfusion are to correct anaemia, suppress erythropoiesis, allowing 
normal growth and development and inhibiting increased gut iron absorption (46).  The first iron 
chelator Desferal (Desferrioxamine, Deferoxamine) was introduced more than 40 years ago (47) 
and has been available in the UK since1964 (48).  
Daily intramuscular injection of 20–25 mg/kg/day stabilised body iron load at around 0.65 
mg/kg body weight (49), and improved survival (50).  Initial studies were encouraging and a 
trial of daily long term intramuscular Desferal significantly reduced hepatic iron accumulation 
and slowed the progression of hepatic fibrosis (51). In 1976 it was shown that subcutaneous 
infusion of a higher dose using a portable syringe driver could stabilise body iron load at around 
0.3 mg/kg body weight (52), and by 1980 subcutaneous infusion of an average daily dose of 40–
45 mg/kg/day (usually over 8 to 12 hours on five nights per week) had become standard care in 
the UK. It was hoped that iron chelation with Desferrioxamine would be able to prevent the 
complications and premature mortality as a result of iron overload. The first data on improved 
survival in thalassaemic patients on long-term chelation therapy followed in the 1980s (53). A 
study in the early 90’s demonstrated that treatment with desferioxamine when used in amounts 
proportional to iron burden, delayed cardiac complications and improved longevity (54). 
Brittenham’s group performed similar work, again demonstrating the early use of 
desferrioxamine in an amount proportional to the transfusional iron load reduces the body iron 
burden. This helped protect against diabetes mellitus, cardiac disease, and early death in patients 
with thalassemia major (18). If instituted in time, intensive chelation therapy with Desferal can 
prevent cardiac complications (23;55;56), and reverse the deleterious effects of severe iron 
overload (45;57-59). Further studies have demonstrated survival extension with long term 
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desferioxamine therapy (18;60;61). Desferal revolutionised the treatment of iron overload in 
thalassaemia, but it soon became clear that open ended life expectancy was not occurring. As 
recently as the year 2000 life expectancy was still severely reduced with only 50% of 
thalassaemia major patients surviving beyond the age of 35 years (50), and with inadequate 
chelation, only 30% survived over the age of 30 (17). (Figure 2.3). By far the commonest cause 
of death was cardiac complications, accounting for well over half of all deaths (62).  The 
disappointing mortality statistics (50) are due to a combination of factors: late presentation of 
cardiac disease, difficulties in assessing myocardial iron, and difficulties in compliance with 
Desferal treatment (61). Desferal has to be given as prolonged intravenous or subcutaneous 
infusions which are painful, cumbersome, and inconvenient. These problems have a knock on 
effect with reduced compliance, particularly during the adolescent years, a time when iron 
burden is often at its highest. Poor compliance and problems with accurate iron assessment have 
resulted in poor outcomes as a result of cardiac iron overload.  Patients and families had a 
“hope” for an oral therapy. An orally active chelator was expected to improve compliance, and 





















Figure 2.3 From Modell et al, Lancet 2000: 355: 2051-2.  Thalassaemia survival curves in 
the UK. Prior to transfusion therapy patients died in early childhood.  Following the 
introduction of chelation therapy, patients died in their teens from iron-induced heart 
failure.  The cohort born between 1945-54 died from iron overload until the introduction 
of Desferal.  The cohort born 1965-74 should demonstrate the results of chelation therapy.  
Initial survival was promising but there has been 25% mortality in the last 5 years: 
survival for this cohort is only 50% to age 30. 
 
 
2.5 ALTERNATIVE IRON CHELATORS 
The orally active chelating agent Deferiprone (1,2-dimethyl-3-hydroxyyrid-4-one) has been 
available since the late 1980’s and has undergone evaluation in a number of countries including 
UK, Canada & India (63-66). Formal dose response studies have shown that iron excretion with 
Deferiprone is inferior to that with desferrioxamine, but intermediate term clinical trials have 
demonstrated its effectiveness (66-69), equivalent urinary iron excretion compared to 
desferioxamine (65;67) and urine iron excretion greater than 25mg iron daily (the mean daily 
intake of iron from transfusion) (64). A meta-analysis of deferiprone trials found that overall, 
Deferiprone had clinical efficacy in achieving negative iron balance and reducing body iron 
burden in highly iron overloaded patients (70). In addition after an average of 16 months of 
deferiprone in doses > or = 75 mg/kg/day, most patients had a decrease in ferritin concentration 
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(71). However a longer term trial of 18 patients over 4.6 years (72), showed that 8 patients had 
hepatic iron concentrations above 80µmol/g liver wet weight, a value previously believed to be 
associated with an increased risk of cardiac disease (18). However the mean liver iron fell from 
a mean of 88.7±12.1 to a mean of 65.5±7.9µmol/g liver wet weight.  Therefore, although the 
number of patients with high liver iron levels was disappointing, treatment with Deferiprone 
appeared to be effective in reducing mean liver iron concentrations.  Deferiprone has been 
licensed in Europe as a second line agent since 1999, although its use has been hampered by 
initial concern regarding hepatic fibrosis (72). These initial fears have been unfounded (73). 
Deferiprone has now been available in all European countries since 1999 as second line 
treatment for those who can not tolerate or have an unsatisfactory response to desferioxamine. 
The commonest cause of death in thalassaemia is cardiac, the primary aim of chelation therapy 
therefore is to reduce the cardiac iron burden and hence prevent premature death as a result of 
cardiac siderosis. Historically risk of cardiac siderosis was assessed by means of high ferritin 
levels >2500 ucg/l and high liver iron measures from liver biopsy >15gm/100gm dry weight. 
Telfer’s group followed a cohort of thalassaemia patients whom had previously undergone liver 
biopsy. They monitored their trend in serum ferritin over a median follow up of 13.6 years and 
compared it with their mean serum ferritin and their liver iron concentration. The clinical end 
point of death or cardiac failure was significantly associated with increasing iron load using all 3 
measures (74). Their data show that iron quantification from a single liver iron biopsy had little 
value in the long term monitoring of iron stores (74). Their data did support the concept that 
keeping a low ferritin is beneficial, most complications being avoided if ferritin was kept 
<1500mcg/l (74). We now know that although some assessment of risk can be extrapolated from 
these measures of iron exposure they are both imprecise surrogate estimates for cardiac iron 
load. In fact evidence from cardiac MRI studies has elegantly demonstrated the discordance 
between iron load in the heart and liver (75). Tissue iron evaluation can be dependant on when 
 19
the assessment is made. Iron metabolism, storage and overload are dynamic processes which 
vary with time and treatment. Depending on when in the cycle the assessment is made (Figure 
2.4), iron loading may be predominantly in the liver, heart or in both organs.  
Liver – iron loaded
Heart – no iron
Liver – no iron
Heart – no iron
Liver – iron loaded
Heart – iron loaded
Liver – no iron












Figure 2.4 Schematic demonstrating variable tissue iron burden depending on timing of 
assessment.  
 
Wonke et al published the first trial data of combination therapy demonstrating increased iron 
excretion compared with desferioxamine monotherapy. Their work suggested an additive, 
synergistic iron chelation effect when added to desferioxamine (76). Subsequent work suggests 
that long-term chelation with Deferiprone may be better at reducing myocardial iron burden 
(77;78). Anderson et al showed, despite significantly higher liver iron levels, a long term 
Deferiprone treated group had lower myocardial iron concentrations and corresponding better 
left ventricular ejection fractions (77). This reinforces the notion that myocardial iron and 
ventricular function should be the prime determinants of assessing the effectiveness of chelating 
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agents.  Similar findings were documented in a study by Piga et al with significantly less cardiac 
disease in patients managed with long term Deferiprone (78). In this study, the 2 patients with 
the worst NYHA class for heart failure were on Desferal. None of the Deferiprone treated 
patients died during the study period, whereas 3 patients in the Desferal arm died of worsening 
cardiac disease. Moreover, compliance was 85% for Desferal treated patients and only 4% 
higher with Deferiprone, suggesting Desferal compliance is unlikely to be the prime explanation 
of this effect. A study by Telfer et al has suggested that Deferipone may be responsible for the 
increased survival seen in a cohort of thalassaemia patients from Cyprus (79). 
Deferiprone is a smaller molecule with a lower molecular weight and lipophilicity (80;81). It is 
proposed that these features enable the molecule to penetrate cell membranes more easily than 
desferioxamine. This may explain its greater cardiac protection as the molecule enters the 
myocardial cells where iron is stored in lysosomes as ferritin and haemosiderin(82). Conversely, 
in the liver, desferrioxamine has the advantage of facilitated transport into cells via an active 
uptake mechanism. 
 
2.6 REVERSIBILITY OF TISSUE IRON OVERLOAD 
The potential reversibility of iron induced cardiomyopathy was first documented in case reports 
of patients with hereditary haemochromatosis treated with recurrent venesection (83) (84;85).  
Subsequently, improvement of ventricular dysfunction with chelation therapy have been 
reported in a patient with megaloblastic anaemia (86), in thalassaemia major (87) and in three 
patients with transfusional iron overload (88). Freeman et al reported that high doses of 
subcutaneous desferioxamine reversed subtle exercise induced dysfunction (57) detected in 
those with normal resting function. The use of subcutaneous Desferal has also been shown to 
reverse moderate left ventricular dysfunction (57;59;89), and advanced, NYHA grade 4, heart 
failure (86). More recently, improvements in patients presenting with rapidly progressive heart 
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failure complicated by arrhythmias have been reported on conversion from subcutaneous 
Desferal to high dose intravenous Desferal (87;90). 
At a cellular level, studies of cardiac myocytes have shown that Desferal can remove iron from 
the cardiac myocytes, reverse lipid peroxidation (32;38), and reverse the iron-induced 
abnormalities of cellular contractility and rhythmicity (91). However, the reversibility of iron-
induced cardiac failure has not been universally accepted, partly due to the high mortality of 
patients presenting with advanced cardiac failure despite chelation treatment (88) and more 
recently by those questioning the role of iron in thalassaemic cardiomyopathy (24;92). Despite 
some uncertainty and failure of a universally agreed consensus, there is overwhelming evidence 
that iron is the culprit and clinically the important problem that needs to be dealt with. 
 
2.7 METHODS FOR ASSESSMENT OF TISSUE IRON LOAD 
Different organs have different susceptibility to iron deposition. With this in mind it is no 
surprise that there remains no single ideal method for evaluating tissue iron burden (93;94). Iron 
deposition varies both between and within different organs. Given the variation between organs, 
assessment of iron in one organ, usually the liver may not accurately reflect the state of other 
organ systems (Figure 2.4).  
Previously body iron stores were estimated by ferritin measurement as an indirect marker. A 
level of >2500 ucg/l was considered to represent high total body iron and risk for cardiac events. 
However, although in normals, serum ferritin correlates with iron stores (95), and with liver iron 
measured directly by liver biopsy (96), there are several factors that distort this relationship in 
thalassaemia major. First, liver fibrosis and transfusion transmitted viral hepatitis reduce the 
effect of iron status on serum ferritin by about 50% (97); Second, ferritin is an acute phase 
protein and subject to elevation during periods of infection or inflammation (98), leading to false 
assessment of high body iron stores. Third, vitamin C deficiency is common in these patients 
and leads to falsely low elevations in serum ferritin despite extensive iron loading (99). It is 
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increasingly recognized that reliance on this test may lead to errors in management; changes in 
body iron account for little more than half the variation in serum ferritin concentrations (97). 
Serum ferritin has more recently been shown not to correlate with myocardial iron load (75).  In 
groups, long term averages of ferritin can differentiate high risk from intermediate and low risk 
groups (74). However, more recently it has been shown that individual measurements of ferritin 
do not correlate well with myocardial iron load, determined by cardiac magnetic resonance 
T2*(75).  
The current gold standard for determining hepatic iron is by direct measurement from a liver 
biopsy (100), an invasive technique with a low but recognised complication rate. A level of 
>15mg/kg dry weight was considered to suggest those at risk of cardiac complications. Iron is 
unevenly distributed even in the non-cirrhotic stage (101-103).  This non uniform distribution of 
iron (104) means a single biopsy may not reliably reflect mean hepatic iron concentrations (105) 
and the result should be interpreted with caution when monitoring the efficacy of chelation 
therapy (106). Furthermore, measurement of liver iron can only be an effective indicator of 
cardiac iron stores if iron is assumed to be stored predictably and homogeneously throughout the 
body. Initial reports suggested such a correlation between myocardial and hepatic iron burden 
(107;108), but it now seems that this is not the case (Figure 2.5), (65;75;109;110). Equally, those 
with a low ferritin and liver biopsy result were felt to be at low risk for cardiac involvement, 
again, this has now been shown to be incorrect (111). 
 
2.8 DIRECT ESTIMATION OF CARDIAC IRON LOAD 
Endomyocardial biopsy can be used to evaluate iron deposition in the heart in thalassaemia 
(112;113). However, as a technique, it is less than ideal, being invasive and having associated 
complication risks. As discussed, iron is deposited in a non uniform manner and therefore the 
risk of sampling error is high, a negative biopsy does not exclude significant cardiac iron. In 
addition the biopsy is of the endocardium giving rise to a potential sampling error, as iron is 
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preferentially deposited in the epicardium (114). Biopsies are taken from the right ventricle 
which is relatively spared from iron infiltration (11;115;116) and may not represent true risk. 
 
 
Figure 2.5 The discordance between liver and cardiac iron is seen in this series of 
MR images where in each case iron deposition leads to a dark appearance of the 
relevant tissue.   
 
 
2.9 ECHO MEASURES OF CARDIAC IRON OVERLOAD 
For many countries the mainstay of assessing cardiac involvement in thalassaemia is by 
transthoracic echocardiography (TTE). This technique is widely available, of relatively low cost 
and has the advantage of being available at the bedside. TTE uses high frequency ultrasound 
waves to obtain real time moving images of the heart. From the images obtained the chamber 
sizes, contractility and valve function can be studied and quantified. As a technique it does have 
some limitations, mainly being user dependant and being subject to poor ultrasound windows 








may limit image acquisition and quality. However, whilst TTE is an excellent modality for 
assessing cardiac function, the main question of interest is in identifying those with cardiac iron 
loading who are at risk of abnormal cardiac function and cardiac decompensation. 
Conventional echocardiograpic markers of left ventricular (LV) function have traditionally been 
used as a surrogate marker to predict the degree of cardiac iron loading. On the whole they have 
been unhelpful. M mode techniques for evaluating LV systolic function have remained normal 
(117;118), and have failed to identify thalassaemia patients with iron overload from normal 
controls. Once abnormalities in LV systolic function become detectable, significant iron 
deposition has occurred and survival is reduced, suggesting that this occurs at a late stage in the 
disease process (119-122). Measures of diastolic function, ventricular relaxation, may occur 
earlier (123-125), and detailed analysis of digitised M mode tracings have detected 
abnormalities in contraction and relaxation in thalassaemia major children (126). Other echo 
techniques involving dynamic studies have highlighted abnormalities of function not apparent at 
rest (127;128). Newer techniques for assessing ventricular function include tissue Doppler 
imaging (TDI). TDI involves obtaining regional information regarding wall motion and velocity. 
A previous study by our group (Vogel et al (129)) involving a sample of 52 thalassaemia 
patients attending our specialist clinic found that TDI detected regional abnormalities despite 
normal global LV function in a high proportion of patients with iron overload. This suggests that 
TDI may be able to identify abnormalities in asymptomatic patients with iron overload. It is 
known that if cardiac dysfunction is identified and intensive iron chelation instituted, that the 
cardiomyopathy associated with iron overload is reversible and cardiac function can improve 
(45), but it is a slow process (45). Recent MRI studies have examined the relationship between 
iron and right heart function. In the absence of significant cardiac iron, T2* >20ms, right 
ventricular (RV) function was normal in 98% of the study group (130). When RV function in a 
thalassaemia population was compared with an age matched group, the function and volumes 
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were found to be higher (131). Little is known regarding echo assessment of right heart function 
in this group of patients. 
 
2.10 CARDIAC MRI ASSESSMENT OF IRON LOAD 
Magnetic resonance (MR) scanning is currently the only method shown to be reliable and 
accurate to assess both hepatic and myocardial iron loading as iron is not predictably distributed 
between the tissues (75;132-135). It has been available in the United Kingdom since 1999 and 
has rapidly become the gold standard for assessing cardiac iron status. Cardiac MRI assessment 
has played a major role in driving changes in the intensification and guiding individualisation of 
iron chelator therapy. This is likely to be the most significant contributor to the improved 
survival seen in thalassaemia since 1999 with a reduction in deaths from cardiac iron overload 
(2) (Figure 2.5, 2.6).  
 
Figure 2.5 (2). Number of deaths of patients with thalassaemia major in the UK by 
interval. In early periods the main cause of death was anaemia. When transfusion 
became usual practice, iron overload became the major cause of death. In 1999 T2* 
cardiac MRI was introduced, clinicians were made aware of the high cardiac death rate 
and new options for oral iron chelation. Since 2000 there has been a 71% reduction in 





Figure 2.6 (2).  Modell’s recent work has demonstrated the improvements in survival 
since their original registry data. The average life-expectancy was 17 years in 1970, 27 
years in 1980 and 37 years in 1990. Since 2000 over 80% of patients have a life 
expectancy of more than 40 years. 
 
 
Anderson et al were the first to demonstrate the clinical utility of cardiac magnetic resonance 
imaging to measure cardiac iron (T2*) and function (75). In this study they clearly demonstrated 
the lack of correlation between serum ferritin and liver iron and cardiac iron loading. This 
helped explain why some patients, whom by these surrogate markers were previously thought to 
be at low risk for cardiac complications, would still succumb to cardiac failure and early 
mortality. A number of other studies have also demonstrated the value of cardiac MR techniques 
in the assessment of cardiac iron overload and function (136-138). Many centres worldwide are 
utilising the same T2* or similar techniques for cardiac iron assessment. The T2* technique is 
transferable and reproducible between different machines and countries (139), giving 
comparable results. It is widely accepted that a T2* of greater than 20ms indicates no clinically 
significant cardiac iron. Original work with the T2* technique had categories of <8ms indicating 
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severe cardiac iron, 8-12ms indicating moderate cardiac iron and 12-20ms indicating mild 
cardiac iron. For our study we used the same classification. The categories have now been 
adjusted and a T2* of <10ms is accepted to indicate severe cardiac iron with 10-20ms being a 
mild to moderate load. Cardiac MRI has many advantages as a technique. It is non invasive, 
robust, accurate & reproducible. It also allows the comparison of iron load and heart function. 
As the gold standard it can be used in trials and studies as the comparison arm to determine the 
predictive ability of other measures, the compliance of patients and the impact of red cell 
consumption. It is also used to guide chelation therapy that is individualised according to risk 
and may be employed to monitor the impact of treatment.  
 
2.11 CARDIAC TREATMENTS IN THALASSAEMIA MAJOR AND CARDIAC SIDEROSIS 
There is only a limited evidence base for specific cardiac medications in iron overload or its 
resultant cardiac failure. Standard heart failure medications are utilised. Recommended 
treatment is with diuretics, angiotensin converting enzyme inhibitors, beta blockers, digoxin & 
spironolactone, the hallmark therapies for other causes of heart failure. Karnouvis et al studied 
the use of enalapril in asymptomatic or minimally symptomatic patients with LV dysfunction 
from thalassaemia. They found enalapril to be well tolerated and demonstrated significant 
improvements in systolic function (140). Whether this translated into improved survival requires 
further evaluation (141). Animal work has proposed the role of L type calcium channels in the 
development of cardiac siderosis (142) and a group from Canada has demonstrated that 









CHAPTER 3: TISSUE DOPPLER TECHNIQUES 
 
3.1 TISSUE DOPPLER TECHNIQUES 
Tissue Doppler techniques include Tissue Doppler imaging (TDI), Strain, Strain Rate and 
Longitudinal Deformation (TT). Over the past decade there have been numerous studies 
published addressing the feasibility and potential clinical applications of TDI and its derived 
techniques of strain and strain rate. Despite this promising expanse of research and publications 
(144-147) the parallel clinical uptake of these methods never really took place and they remain 
largely confined to high technology research oriented echo laboratories. TDI allows the analysis 
of velocities with high amplitude and low frequency which originate from the myocardial tissue. 
The method depicts myocardial motion, measured as myocardial velocity, at specific locations 
in the heart. Tissue velocities indicate the rate at which a point in the myocardium moves toward 
or away from the transducer. These signals are not detected in the traditional Doppler 
examination. TDI is achieved by gain adjustment and elimination of the high pass filter and 
requires modifications of the software and hardware of the ultrasound platform. Integration of 
velocity over time yields displacement or the absolute distance moved by that point. Tissue 
Doppler derived velocities can be obtained by many methods, the commonest being pulsed 
Doppler (a sample volume placed at a particular point) and colour Doppler. If colour Doppler is 
used tissue velocity information is acquired from the whole sector and therefore multiple 
locations can be interrogated simultaneously. Both these methods give the same mechanical 
information but differences exist in the peak values obtained. Pulsed Doppler techniques 
measure peak velocity approximately 20-30% higher than the mean velocity obtained with 
colour Doppler. This difference must be considered when for example estimating left ventricular 
filling pressure using the E/E’ ratio (148). It is also of importance when comparing velocities 
obtained in 1 study with those from another study where an alternative method may have been 
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used to derive the velocity information. For our study we have used the colour Doppler 
technique with subsequent offline analysis (Figure 3.1).  
 
Figure 3.1 A – Pulsed wave Doppler TDI, B – Colour Doppler TDI, C – Tissue 
Velocities (S’ – Systolic Velocity, E’ – Early Diastolic Velocity, A’ – Late Diastolic 
Velocity, D – Maximum Tissue Displacement 
 
Tissue Doppler has been validated extensively and examined in a variety of settings (149;150). 
Most recent work has almost exclusively interrogated tissue velocities in the longitudinal 
direction (from the apical projections). From apical projections the apex is relatively fixed and 
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immobile, whereas the base moves towards the apex in systole and away in diastole. The 
differential movement between base and apex results in a velocity gradient with the highest 




Figure 3.2– Demonstrating the myocardial velocity gradient with higher velocities 
at the base and lower velocities at the apex. Strain rate SR is calculated as the 
difference between 2 tissue velocities normalised to the distance between the 2 
velocities (151). 
 
One of the main reasons for scepticism towards TDI lie in its physical principles. Doppler is the 
ideal method for examining intracardiac and vascular flow that obeys the laws of fluid 
dynamics. Myocardial motion is different, occurring in multiple planes and directions. It is 
influenced by motion of other organs and structures within the thoracic cage and follows 
complex mechanical phenomena for which there exists no reference method (152). TDI 
interrogates motion at a single point with reference to the transducer (outside the chest wall). It 
is influenced by translation forces and tethering (the motion of an abnormal basal segment is 
influenced by the pull of a normal apical segment towards the apex) (146). TDI has however 
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refocused attention on some regional contraction phenomena such as delayed systolic 
contraction or late systolic contraction.  
 
3.2 STRAIN AND STRAIN RATE IMAGING 
The limitations of TDI in respect of tethering from collateral segments can be overcome by 
strain imaging. Strain is a measure of tissue deformation and is defined as the change in length 
normalised to the original length. If the segment gets shorter in length then the strain is –ve. If 




Figure 3.3 – Lo – Original segment length, L1 – New segment length.  
 
Strain imaging introduced the concept of myocardial deformation as a marker of contractility 
intrinsic to the myocardium. Strain rate is the speed at which this change occurs. Strain rate and 
strain are similar to shortening velocity and shortening fraction respectively. By TDI strain rate 
is the difference in velocity between 2 points along the myocardial wall (velocity gradient) 
normalised to the distance between the 2 points. Strain rate measures the rate at which 2 points 
move toward or away from each other. Integration of strain rate yields strain, the normalised 
change in length between 2 points.  But strain is not without its limitations. As it is derived from 
TDI, limitations in terms of angle dependency apply. In addition, the signal is subjected to noise 
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problems especially in the apical views. This affects the profile of the spectral curve and can 
make interpretation difficult and reproducibility very challenging.  Strain rate and strain are 
theoretically less susceptible to translational motion and tethering artifacts and thus may be 
superior to tissue velocity in depicting regional or global myocardial function. In general peak 
systolic strain rate comes closest to measuring local contractile function. It is relatively volume 
independent and less pressure dependent than strain. In contrast peak systolic strain is volume 
dependent (151).  
 
3.3 VALIDATION OF TDI AND STRAIN TECHNIQUES 
TDI and its derived methods have very high temporal resolution. They can analyse events that 
happen in such a short period of time that they are missed by the human eye (146;147;147) 
These phenomena inherent to myocardial contractility have been addressed with methods used 
in experimental studies such as sonomicrometric techniques (153) , which are not reproducible 
in a clinical setting and therefore cannot be defined as reference methods. The real problem 
consists in the lack of a definition of myocardial contractility and of a gold standard that 
identifies it. Tissue Doppler– derived strain variables have been validated with gel phantoms 
(154) isolated muscle preparations (155),  and tagged CMR imaging (156) Normal strain and 
strain-rate values have been published (157). 
 
3.4 2D STRAIN (SPECKLE TRACKING) 
This is the latest technique proposed for obtaining velocity and deformation information. The 
method rather than analysing the long component along the line of the image estimates vectorial 
velocities. The algorithm tracks data from radiofrequency and black/white signals. For every 
pixel of the image an angle independent velocity is estimated and follows in the various frames. 
This could enable 2D strain to overcome the sampling and angle dependency errors of strain 
obtained by Doppler.  
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3.5 THE ROLE OF TDI AND STRAIN TECHNIQUES IN OTHER CARDIAC PATHOLOGIES 
Tissue Doppler and strain techniques have an expanding evidence base for their use in other 
areas. 
 
3.5.1 Global Systolic Function. 
 
The current gold standard for systolic function remains the ejection fraction although this is 
subject to many limitations. Peak annular mitral velocity correlates well with dP/dTmax by 
micromanometer catheters in the LV cavity and with ejection fraction from angiography and 
radionuclide imaging (158;159). Normal values for tissue Doppler derived velocities have been 
established (160;161). A peak mitral annular velocity of >5.4cm/s averaged from 6 annular sites 
predicts an EF > 50% (158). Strain rate closely correlates with invasively determined parameters 
of global function (162), thus either of these techniques could potentially be used instead of 
ejection fraction to quantify global function. Visual assessment of wall motion abnormalities 
suggestive of myocardial ischaemia are variable and have poor reproducibility (163). Both TDI 
and strain can quantify wall motion. Low systolic tissues velocities correlate with angiographic 
and echocardiographic wall motion abnormality (164). Tissue velocities decrease with reduced 
regional perfusion, recover on reperfusion, and differentiate between transmural and 
nontransmural infarction (165-167).  Regional strain rates and strain are reduced in ischemia and 
infarction (168;169). Strain and strain rate identify infarcted segments and correlate with extent 
of transmural infarction (170). Strain and strain rate are less susceptible to cardiac translational 
motion and tethering. The term “tethering” is used to describe the dragging of an akinetic basal 
segment toward the apex by normally functioning mid or apical segments. This theoretical 









There has been considerable interest in the role of tissue Doppler techniques in the assessment 
and management of cardiomyopathies. Tissue velocities, strain rates and strain are reduced in 
cardiomyopathies and could potentially be used for preclinical detection of inherited 
cardiomyopathies. In rabbit models of hypertrophic cardiomyopathy systolic and diastolic 
velocities were significantly reduced (172). In patients with known mutations associated with 
hypertrophic cardiomyopathy, but without ventricular hypertrophy reduced systolic and diastolic 
velocities (173) or reduced early diastolic velocities have been found (174). Early diastolic strain 
rates were significantly lower in asymptomatic gene positive patients with Friederichs ataxia 
(175), are lower in hypertrophic cardiomyopathy patients compared with athletes or normal 
subjects (176) and are lower in restrictive than in normal or constrictive cardiomyopathy (177). 
In Fabry’s disease abnormal systolic and diastolic velocities are reported (178) and systolic 
strain and strain rate improve after enzyme replacement therapy (179). In primary amyloidosis 
tissue velocities and strain rates are reduced with or without evidence of cardiac involvement 
(180-182). A previous study by our group (183) involving a sample of 52 thalassaemia patients 
attending our specialist clinic found that TDI detected regional abnormalities despite normal 
global LV function in a high proportion of patients with iron overload. This suggests that TDI 
may be able to identify abnormalities in asymptomatic patients with iron overload. 
 
3.5.3 Dysynchrony Analysis 
 
There have been a number of studies demonstrating benefit from cardiac resynchronisation 
therapy in patients with symptomatic heart failure despite optimum medical therapy, low 
ejection fraction and conduction abnormality (184;185). A prolonged QRS duration from 
electrocardiogram is used to identify electrical dysynchrony. However there are a proportion of 
patients who do not derive symptomatic improvement, so called “non responders”. It is widely 
accepted that electrical dysynchrony does not necessarily correlate with mechanical 
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dysynchrony, which is ultimately what resynchronisation therapy is aimed at improving. Several 
reports suggest a low concordance between electrical and mechanical synchrony (186;187) 
Mechanical dysynchrony identified by echocardiography and in particular by tissue Doppler 
techniques may be superior to electrocardiography in identifying responders and non responders 
to this important beneficial therapy (188;189). Tissue Doppler imaging allows the operator to 
analyse mechanical activity and measure for example the time to onset of peak systolic motion 
at various locations in the heart. In the normal synchronous heart, the time to peak velocity 
occurs simultaneously in the different locations (Figure 3.4, panel A). In dysynchronous hearts, 
the time to peak systolic motion varies from segment to segment and usually the lateral and or 
posterior segments peak considerably later than the septum, resulting in inefficient contraction 
and ejection (Figure 3.4, panels B & C). Pacing of the delayed segment allows the mechanical 





Figure 3.4 – A = Normal Subject, B = Subject with heart failure, C = Subject prior 
to biventricular pacing, D = Patient C after biventricular pacing (151). 
 
Severe mechanical dysynchrony may be seen visually but milder forms are not detected by eye 
and cannot be quantified by eye. The mechanical delay between early and late contracting 
segments predicts response to resynchronisation therapy (190). There have been a number of 
proposed indices of mechanical dysynchrony, the criteria commonly used in clinical practice are 
the septal to lateral wall delay of >65ms (189) and the standard deviation of time to peak of 
systolic velocities in either a 12 (191) or 16 segment model (192). It is not clear whether TDI or 
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strain/strain rate are superior in predicting response to cardiac resynchronisation therapy 
(193;194).  
 
3.5.4 Diastolic Function 
 
Early diastolic velocities (E’) correlate with invasive measures of diastolic function (195-198). 
However, although initially thought to be load independent this is not the case (196;199). Low 
Ee’ of < 3.5cm/sec in the hypertensive population and <3.0cm/s in patients with low ejection 
fraction predicts mortality and is incremental to clinical and echocardiography data (200;201). 
The ratio of mitral inflow E to E’ velocity ratio (E/Ee’) correlates closely with left ventricular 
filling pressure (195;202), predicts heart failure events and is incremental to clinical factors and 
ejection fraction (203). The higher temporal resolution of strain imaging allows interrogation of 
short diastolic mechanical events. A ratio of early to late diastolic strain rates can be calculated 
for different ventricular segments. In global diastolic dysfunction the number of segments with 
abnormal ratios is increased and as the diastolic function worsens the number of abnormal 
segments increases (204).  
 
3.5.5 Right Ventricular Function 
 
Estimation of right ventricular function by echocardiography is an area which is challenging and 
often overlooked in clinical practice. Tricuspid annular planar systolic velocity (TAPSE) 
correlates with right ventricular ejection fraction (205;206). TAPSE reflected RV function and 
predicted 2 year survival in patients with pulmonary hypertension (207). More recent data 
suggest a relationship between isovolumic acceleration and regional contractility (208). Tissue 
Doppler derived RV displacement and strain closely correlate with RV stroke volume and can 
track changes in RV function during vasodilator infusion (209).  
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3.6 TDI TECHNIQUES IN THALASSAEMIA PATIENTS 
These techniques are evolving and have been demonstrated to have a role in a number of 
conditions (172;173;175;176;178;180;181). Previous work has demonstrated that TDI detected 
regional abnormalities despite normal LV function in a cohort of thalassaemia patients. These 
techniques are less dependent on image quality to assess ventricular function, as the signal is of 
a high amplitude and low velocity, being generated by myocardial wall motion. These 
techniques are relatively straightforward to apply even for those learning the techniques. As 
thalassaemia leads to tissue iron accumulation, it may be expected to cause abnormalities in 
tissue Doppler signals at an early stage. Most thalassaemia patients are monitored on a periodic 
basis with up to date transthoracic imaging. These techniques take little time to acquire the data 
which can be subsequently analysed off line, thereby adding little extra scanning time to gather 
the information. These methods therefore lend themselves very well for application in the 






CHAPTER 4: BRAIN NATRIURETIC PEPTIDE 
 
4.1 BRAIN NATRIURETIC PEPTIDE 
Brain natriuretic peptide (B-type natriuretic peptide, BNP), is predominantly a cardiac hormone 
released in response to increased wall tension, stretch and ventricular volume expansion. Brain 
natriuretic peptide, in the active form is a 32 amino acid polypeptide containing a 17-amino acid 
ring structure common to all natriuretic peptides (210).  
 
 
Figure 4.1 Release of BNP (Biosite website) 
 
The major source for BNP is in the ventricles (211) (Figure 4.1), suggesting it may be a more 
sensitive and specific indicator of ventricular dysfunction than other natriuretic peptides (212-
214), such as atrial natriuretic peptide, (ANP) which is stored in both the atria and ventricles and 
C-type natriuretic peptide, (CNP) which is of endothelial origin (215). BNP is synthesised and 
released in bursts (216). The release is stimulated by increases in ventricular wall tension or 
stretch (217),, and is directly proportional to ventricular volume expansion and pressure 
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overload (213;218-220). The level of gene expression & tissue concentration of BNP increases 
in all cardiac regions but predominantly in the left ventricle in animal models (221). Taking 
atrial and ventricular weight into account, the total amount of BNP mRNA (messenger 
ribonucleic acid) in the ventricle represents 77% of that in the whole heart (222). On secretion, 
proBNP is cleaved into the inactive N-terminal-proBNP of 76 amino acids and the 
endocrinologically active BNP-32 (223). 
BNP opposes the adaptations to congestive cardiac failure (CCF) by promoting diuresis, 
natriuresis, and vasodilatation, inhibiting the sympathetic and renin-angiotensin axis and 
inhibiting the synthesis of vasoconstrictor molecules (224), thereby attempting to restore 
haemodynamic and circulatory balance. Attempts have been made to utilise hormones to 
diagnose and monitor the progress of heart failure and the neurohormonal natriuretic peptide 
group appear to be appropriate candidates for neurohormonal profiling (213;225),  and thus far, 
show great promise. In addition, there is increasing evidence for the role of BNP in assessment 
of prognosis following acute myocardial infarction (226). 
 
4.2 BNP MEASUREMENT IN THE ASSESSMENT AND MANAGEMENT OF HEART FAILURE 
Several studies have shown BNP to be a marker of changes in LV function & BNP levels 
correlate with symptoms of heart failure (227;228). In addition BNP shows an inverse 
correlation with LV ejection fraction as measured by echocardiography. In a large study of A&E 
attendances with breathlessness, BNP levels were able to accurately distinguish between 
breathlessness of cardiac and non cardiac origin (227). By means of receiver operator curves for 
various BNP cut off values, 100pg/ml was found to be the most accurate for differentiating 
dyspnoea due to congestive cardiac failure and dyspnoea due to other causes (227). Maisel et al 
found that BNP levels alone were more accurate than any historical or physical findings with an 
odds ratio of 29 and a level of >100pg/ml giving a diagnostic accuracy of 83.4% (227). Knudsen 
et al subsequently looked at signs, symptoms and risk factors for heart failure in patients 
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presenting with acute dyspnoea to A& E departments. They found that a BNP of >100pg/ml had 
the highest odds ratio of 12.3 for a diagnosis of heart failure as the cause of dyspnoea (229), 




Figure 4.2 Multivariate Predictors Of Heart Failure As A Cause Of Acute Dyspnoea 
(229). 
 
Other work has shown BNP levels to be an independent marker of prognosis in patients 
admitted with exacerbations of heart failure (230), and high levels of BNP are associated with 
sudden cardiac death in patients with chronic heart failure (231). BNP levels can be monitored 
to reflect response to treatment, patients with symptomatic improvement but with persistent 
elevation of BNP were at higher risk of adverse cardiac events (232-234).  In a prospective 
study with symptom guided therapy versus BNP guided therapy the later group had lower rates 
of cardiac events over the follow up period (235). 
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4.3 THE ROLE OF NATRIURETIC PEPTIDES IN THE ASSESSMENT AND MANAGEMENT OF 
THALASSAEMIA PATIENTS 
 
There are relatively few studies investigating the role of natriuretic peptides in the assessment of 
thalassaemia patients. A group from Italy studied levels of atrial natriuretic peptide (ANP) in 
asymptomatic thalassaemia major patients and compared them with age matched controls. They 
found significantly higher levels of ANP in the thalassaemia major groups compared with 
controls (236). Blood transfusion was associated with a significant increase in ANP value (236). 
An ANP value greater than 2 standard deviations above the mean value of the control group 
correlated with the presence of diastolic dysfunction on Doppler echocardiography(236). This 
was the first suggestion that natriuretic peptides may have some utility in assessing patients with 
myocardial involvement. At the time of our study there had been no previous work exploring the 
utility of BNP in thalassaemia patients.  
 
4.4 BNP OR PRO BNP 
On secretion Pro BNP is cleaved into the inactive pro BNP (N Terminal Pro BNP) a 76 amino 
acid polypeptide and the endocrinologically active BNP, a 32 amino acid polypeptide. Although 
BNP and NT pro BNP are two different peptides they show high correlation in patients with 
acute dyspnoea (237-240). The Biosite point of care BNP assay was available 3 years earlier 
than the first clinical assay for NT –Pro BNP, therefore it comes as no surprise that the majority 
of available evidence and experience is with the BNP assay. Over recent years several studies 
have directly compared BNP & NT Pro BNP in patients with acute dyspnoea (237-240). In one 
study BNP was superior to NT Pro BNP, the other 3 studies gave similar accuracy. In the one 
study favouring BNP, the patients recruited were above the age of 65 (240). The importance of 
the clinical experience in an individual institution with one specific marker cannot be 
overemphasised. There is no fixed equation to convert from BNP to NT Pro BNP therefore it is 
difficult to compare the measures and changing from one marker to the other should be 
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discouraged. Over time 3 other manufacturers have produced systems for BNP evaluation and 
one other for NT Pro BNP evaluation. All except the BNP triage meter which is point of care, 
are laboratory based systems. Debate continues as to whether to measure BNP or NT pro BNP 
and whether to use a point of care or laboratory based system. At the time of designing the study 
there was a greater evidence base for BNP assays, and the Biosite Triage meter gave us the 
portability that our study required given that it would take place in Cagliari, Sardinia, Italy. 
 
4.5 WHAT LEVEL OF BNP IS SIGNIFICANT 
The higher the level of BNP or NT Pro BNP, the higher the probability that the patients 
symptoms are caused by heat failure. It has become common place to use 2 cut off values. The 
lower value has a high negative predictive value and is used to rule out heart failure. The upper 
cut off has a high predictive value to rule in heart failure. For BNP the accepted lower cut off is 
100pg/ml with a higher cut off of 400pg/ml. 100 pg/ml has been selected for the lower cut off 
given the high accuracy demonstrated in previous studies. These cut offs apply regardless of 
patient age or sex (241-243), with the exception of renal impairment with GFR of < 60mls/min  
and severe obesity with a BMI of >35 when a lower cut off of 60pg/ml is used (244) to rule out 
heart failure and >200pg/ml to rule in heart failure (245;246). 
 
4.6 THE TRIAGE BNP TEST 
The Triage BNP test is a fluorescence immunoassay that measures B type natriuretic peptide in 
whole blood and plasma specimens with EDTA as anticoagulant. It is a bedside, point of care 
system (Figure 4.3). Requirements are a Triage BNP meter and separate BNP assay strips, 
purchased in packs of 25 test strips and pipettes with a separate reagent code chip for validation 
of test strips (Biosite Incorporated, San Diego, California). The test strips are single use devices 
and give a quantitative determination of BNP in whole blood and plasma specimens. The 
precision, analytic sensitivity, and stability characteristics of the system have been previously 
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Figure 4.3 BNP Triage Meter and Assay Strip 
 
4.7 PRINCIPLES OF THE BNP TEST 
The BNP assays contain the reagents necessary for BNP quantification in whole blood. The 
reagents are murine monoclonal and polyclonal antibodies labeled with a fluorescent dye. 
Whole blood is collected and 250µl are added to the sample port (Figure 4.4). A filter separates 
the plasma and red blood cells. Plasma moves into the reaction chamber to form a reaction 
mixture with the fluorescent antibody (249).  After incubation the mixture moves to a detection 
lane where analyte and conjugates are captured. The concentration of the analyte in specimen is 
directly proportional to the fluorescence detected by the Triage meter (249). The meter is 
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programmed to automatically perform the BNP analysis after the sample has reacted with the 
reagents. The reaction analysis time is around 15 minutes. The BNP value is displayed on the 
LCD screen and printed out. 
 
Figure 4.4 BNP Assay Strip 
 
4.8 TRIAGE METER QUALITY CONTROL 
4.8.1 Built In Controls – Each BNP test device contains 2 internal controls that satisfy routine 
quality control requirements. These controls check for sufficient sample, fluorescent label in the 
detection area, device insertion and device reading by the Triage meter. An invalid result from 
either control gives a warning message for the test to be repeated. These controls are performed 
with each patient sample.  
 
Use Pipette Provided To Add 
250µl Of Blood Here 
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4.8.2 External Quality Controls – The triage meter is supplied with a quality control simulator 
device. It is recommended to perform a simulator test daily to ensure correct function of the 
Triage meter. In addition it is recommended to perform after moving the meter, upon initial 
setup and if any uncertainty over performance. 
4.8.3 Triage BNP Controls – This comes as 2 control solutions, one with a low BNP level, the 
other a high BNP level. These controls check the performance of the BNP test device. It is 
recommended to perform these with each new shipment of BNP device test strips, every 30 days 
or to test the performance of the user or device.  
 
4.9 BNP TEST DEVICE STABILITY 
BNP assays should be stored refrigerated between 2-8°c. If refrigerated, the test device remains 
stable whilst in the sealed pouch until the expiry date printed. On removing from refrigeration, 
15 minutes minimum should be allowed for the device to reach room temperature prior to use. If 
not refrigerated, unopened pouches can be stored for up to 14 days. Once the device is opened 
the blood sample should be added within 15 minutes to avoid too long a period of light 
exposure. It is recommended not to open the device until ready for use. The BNP test device 
should be inserted into the Triage meter within 3 minutes of the sample being added. 
 
4.10 PURPOSE OF STUDY 
With the emergence of the T2* technique there is now an accurate means of assessing cardiac 
iron burden and of monitoring the response to intensive iron chelation. However, given the cost 
implications and limited availability of this technique there remains a requirement for other 
more widely available methods of assessment that are capable of giving a bed-side indication of 
early myocardial involvement. 
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Our aim is to investigate the role of BNP and tissue Doppler echocardiography in the 
management of transfusion dependent thalassaemia patients. We hypothesise that BNP levels 
will increase as the degree of iron loading on cardiac MR increases (corresponding to a decrease 
in the T2* score). In addition, for a given degree of myocardial iron overload, changes in BNP 
level will correlate with changes in myocardial function, and might therefore be used as a 
marker of deteriorating cardiac function and as a marker of response to iron chelation and heart 
failure therapies. There are now many assays for evaluation of BNP including the bedside point 
of care system used in this study. This makes BNP an ideal choice of biomarker to be 
investigated. If a useful relationship is found for BNP, then this could be tremendously useful in 
guiding clinicians as to the likelihood of cardiac iron or of cardiac decompensation in those with 
known cardiac iron loading.  
 
Tissue Doppler imaging is a new echo modality being increasingly used to assess both systolic 
and diastolic function. Data from other cardiac conditions supports its role in the assessment of 
cardiac function. TDI can be incorporated into a standard transthoracic echo evaluation, which 
many of these patients undergo as part of their standard care. In its simplest form, the 
measurement of systolic velocities, the additional time required per study is very small and the 
velocities obtained are easy to understand. It therefore seems to be an ideal parameter to look 
into. We hypothesise that tissue Doppler velocities may decrease as the level of cardiac iron 
increases and that these values may increase again following treatment optimisation and 
enhanced iron chelation.  
 
Brain natriuretic peptide estimation and tissue Doppler echocardiography may fulfil this role 
enabling the early identification of patients at risk of suffering the cardiac consequences of iron 
overload, who may then benefit from aggressive individualised treatment regimes designed to 
prevent the development of heart failure. 
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CHAPTER 5: METHODS 
 
5.1 OVERALL STUDY POPULATION  
5.1.1 Overall Study Population 
This study was performed in collaboration between London, UK and Cagliari, Sardinia as part 
of a larger study (250). Patient recruitment was from 12 thalassaemia centers on the island of 
Sardinia, with patients undergoing local hematology management but travelling to Cagliari for 
the screening and CMR scans. A London-based mobile 1.5-T CMR scanner (Sonata, Siemens, 
Erlangen, Germany) with specialized cardiovascular capability was transported 3 times to 
Cagliari, Italy, for this research. 167 patients underwent a screening CMR to calculate cardiac 
T2*. In addition all screened patients underwent BNP sampling (Biosite Incorporated, San 
Diego, California) and a full transthoracic echocardiogram (GE Vivid 7 Pro, GE, Vingmed, 
Norway) including tissue Doppler techniques. The study protocol was approved by the ethics 
committees in London and Cagliari. Patient information and consent forms were in Italian and 
all participants gave written informed consent obtained with the help of local health care 
professionals.   
 
5.1.2 Severe Cardiac Iron Loading Cohort 
Following screening CMR scans patients were divided into groups on the basis of myocardial 
T2*. Those with T2*>20ms (no cardiac iron loading) were excluded from the trial (n=59). 
Subjects with severe cardiac siderosis, T2*<8ms (n=22) were also excluded from the 
randomization process and were offered best medical treatment, including dual chelation therapy 
based on current best clinical practice and at the discretion of their haematologist. This group 
with T2*<8ms underwent cardiac MRI assessments at baseline, 6 and 12 months to assess 
myocardial and hepatic iron loading (T2*), left ventricular (LV) volumes, and ejection fraction 
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(EF). In addition at baseline, 6 months and 12 months they underwent BNP measurement and 
full transthoracic echocardiography including tissue Doppler imaging. 
 
5.1.3 Mild to Moderate Cardiac Iron Loading Cohort 
Of the remaining 86 patients with T2* between 8-20ms, 65 were subsequently randomised to 
receive either combined therapy (n=32, deferoxamine & deferiprone) or deferoxamine & 
placebo (deferoxamine group, n=33) (Figure 5.1). Investigators were blinded as to the allocation 
of study drugs. These 65 patients returned for follow up assessment at 6 and 12 months. Follow 
up visits included CMR evaluation, BNP measurement and full transthoracic echocardiography. 
 
 
Figure 5.1 – Screening, Randomisation, Completion & Withdrawal Numbers  
 
Inclusion criteria for the trial were 
 Beta Thalassaemia Major 
 Maintaining pre transfusion haemoglobin of 9d/dl 
 Myocardial T2* at screening of 8 to 20ms 
 Male or female  
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 Age > 18years 
 Any ejection fraction 
Confirmation of effective contraception throughout the trial (both men and women) 
 
Exclusion criteria were as follows 
Patients who had previously received deferiprone for a total of more than 6 months over 
the last 5 years 
Patients with previous reaction to deferiprone 
Neutropenia (ANC <1.5 x109/L) at screening 
Thrombocytopenia (<50 x109/L) at screening 
Liver enzymes > 3 times upper limit of normal 
Implant incompatible with MR (such as pacemaker) 
Claustrophobia, or other condition making CMR impossible or inadvisable;  
 Inability to consent 
 
5.2 TRANSTHORACIC ECHOCARDIOGRAPHY PROTOCOL 
5.2.1 Echo Dataset 
All 167 of the screened patients underwent a full transthoracic echocardiographic examination. 
As a large number of patients were scanned over a short time period we had to be selective over 
the views, images and measurements obtained. Left ventricular (LV) dimensions were obtained 
as global parameters of function. Systolic function was quantified by ejection fraction (EF) from 
both M mode (Teicholtz formula) of the parasternal long axis (PLAX) and from modified 
Simpsons technique from the apical 4 chamber (4Ch) view. Diastolic function was assessed 
from the E:A ratio of the transmitral flow. All imaging was undertaken by Dr Nair & Dr Walker 
on a GE Vivid 7 Echo machine (GE Vivid 7 Pro, GE, Vingmed, Norway). Patients were 
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maneuvered into the left lateral position, at a 45 degree angle. Images were acquired during 
quiet respiration and patients were requested to breath hold during unforced mid respiration. 
This was to minimize variations in image acquisition but was not always possible in view of the 
language barrier. For follow up visits at 6 and 12 months all echo studies were performed by Dr 
Nair. A standard echo protocol was followed including the following views; PLAX, parasternal 
short axis (PSAX) & apical 4Ch. 3 cardiac cycles were recorded from each view. All measures 
were made from each of the 3 cardiac cycles and an average taken. From the PLAX view LV 
dimensions and M mode EF were calculated. Anatomical M mode was utilized to ensure a 
perpendicular cut of the basal LV through the tips of the mitral valve and through the aortic root 
and left atrium (LA) in line with standard methodology.  Left ventricular diastolic dimension 
(LVdD), left ventricular systolic dimension (LVsD) and LA size were measured form leading 
edge to leading edge. The maximum LA dimension was obtained at end systole. By Teicholtzs 
formula the M mode EF was calculated. From the apical 4 chamber view, where possible, the 
following measures were made. Ejection fraction was calculated by uniplane Simpsons method 
of summation of discs. LA area was estimated by manual tracing of peak size at end systole in 
the apical 4 chamber view. A pulsed wave Doppler sample was placed at the tips of the mitral 
valve to quantify the velocity of transmitral blood flow during passive ventricular filling (E 
wave, early diastole, passive atrial emptying) and active ventricular filling (A wave, late 
diastole, atrial systole). The ratio of E:A gives an indication of diastolic function. Valves were 
assessed visually, by Doppler and colour flow imaging. Severity of regurgitant jets were crudely 
quantified by visual appearance and size of the jets on colour flow imaging. Right ventricular 
(RV) diastolic dimension was measured from the apical 4 Ch view with an internal dimension 
from the interventricular septum to the right ventricular free wall, measured at the basal region 
just to the ventricular side of the tricuspid valve. The RV free wall function was estimated by 
eye. When tricuspid regurgitation was present, continuous wave Doppler was used to determine 
the peak velocity of the jet. This value when applied to the modified Bernoulli equation gives 
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the peak pressure difference between the right ventricle and the right atrium.  This value was 
used to estimate the systolic pulmonary artery pressures by adding 5mmhg as an estimate for 
right atrial (RA) pressure. Unfortunately due to time constraints subcostal imaging was not 
performed and hence no inferior vena cava imaging was available to give a more accurate 
assessment of RA pressures, hence the use of an estimate of 5mmhg. 
 
5.2.2 Tissue Doppler Imaging Techniques (TDI) 
In addition, images were recorded from 4 chamber views with colour Doppler to acquire tissue 
velocities with subsequent off line analysis. As discussed earlier (Chapter 3) there are 2 methods 
to obtain tissue Doppler information. We chose to use the colour Doppler TDI techniques rather 
than the pulse wave spectral technique which is the usual method used in the literature (Figure 
3.1). Although the colour Doppler technique is recognized to give values of approximately 20% 
lower it is also accepted to give a clearer tracing allowing easier identification and better 
accuracy for the peak velocities. Image quality was optimized by depth, width, gain and tilt 
adjustment to focus on a small sector and to maximize frame rates at greater than 150 per 
second. 3 cardiac cycles were recorded for the LV septum and lateral wall and the RV free wall 
(Figure 5.2). For TDI techniques a frame rate of >150/second is preferred to minimize signal to 
noise ratios. A sample volume of 12mm length was placed in specific locations (the basal and 
mid regions of the LV septum, lateral wall and RV free wall) and manually tracked to wall 
motion through ventricular contraction. Further analysis of TDI images were performed off line 
using Echopac software (GE, Vingmed, Norway), to calculate the following measures, peak 
systolic velocity (Sa), peak early diastolic velocity (Ea), peak late diastolic velocity (Aa) (Figure 
5.2), peak strain, strain at aortic valve closure, early diastolic strain (Figure 5.3), peak strain rate 
taken during systole (Figure 5.4) and peak tissue tracking (TT) at aortic valve closure (Figure 




Figure 5.2 S221 RV Basal TDI Curve 
All measures were obtained for regions of interest (ROI) placed at the base and mid regions of 
the LV septum, lateral wall and RV free wall. From the transmitral and transaortic Doppler 
profiles the following events were marked, MVO (mitral valve opening), MVC (mitral valve 
closure), AVO (aortic valve opening), AVC (aortic valve closure). These events form points of 

























Figure 5.5 OL37 Basal Lateral TT’s 
 
5.2.3 Limitations of measurements obtained. 
Due to constrictions in time as a result of a large number of patients being scanned each day we 
had to select specific parameters for measurement. This raises the possibility of some 
inaccuracies. With respect to evaluation of systolic function we calculated EF with the Teicholtz 
M mode technique. It is recognised that this technique is prone to inaccuracy as it relies heavily 
on the function of 2 specific points, in the interventricular septum and the posterior wall to 
calculate the EF for the whole ventricle. Clearly regional abnormalities in these areas can 
adversely affect the calculated ejection fraction. Our 2nd method of EF estimation used the 
Simpsons technique of dividing the LV cavity into a series of discs, the volume of each one 
TT 
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being calculated then summated together. This process is performed in both diastole and systole 
and the difference in cavity volumes is used to generate the ejection fraction. Simpsons 
estimation is considered much more accurate than the M mode technique and uses a similar 
methodology to that used for volume and function assessment with cardiac MRI (the gold 
standard for volume and EF calculation). However, the preferred technique uses a biplane 
method with apical 4 chamber and 2 chamber volume calculations to maintain accuracy. Again, 
with time constraints we were limited to apical 4 chamber images only. When assessing left 
ventricular diastolic function we chose not to use some of the accepted measures of diastolic 
impairment in favour of others. There remains a great deal of uncertainty regarding the optimal 
measures of diastolic function and a number of the measures are unreliable as they depend of 
preload. We used transmitral E:A ratio which although dependant on preload is perhaps the most 
commonly used measure and widely understood in terms of both what is being measured and its 
limitations. We chose to use tissue Doppler techniques to measure the diastolic velocities (Ea & 
Aa) and to calculate the E/E’ (E/Ea) ratio rather than pulmonary vein Doppler techniques. We 
felt this was an acceptable compromise as the tissue Doppler diastolic measures can be obtained 
in virtually all subjects whereas pulmonary vein Dopplers are subject to good quality imaging of 
the pulmonary veins, which may be suboptimal in a proportion of patients.  
 
5.2.4 Reproducibility Studies 
A number of patients were selected for reproducibility studies. Tissue Doppler velocities, strain, 
strain rate and longitudinal displacemt were calculated, then recalculated by the same operator, 
blinded to the first set of results for intraobsever variability. The data was then reanalyzed by a 
second operator, again blinded to the first set of results for interobserver variability. The results 
were compared to calculate the observer variability. 
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5.3 BRAIN NATRIURETIC PEPTIDE (BNP) PROTOCOL 
5.3.1 BNP Sampling And Analysis 
BNP levels were obtained from whole blood for each patient at each of the assessment visits. 
Patients were rested for at least 30 minutes prior to blood sampling. An EDTA specimen tube 
was used in accordance with the manufacturer instructions. Blood was analysed within 4 hours 
of being taken. Using the pipette provided, 250ul of whole blood is added to the sample port of 
the BNP assay strip. The whole blood reacts with the fluorescent labelled antibody over a short 
period. After the period of incubation and reaction which takes 15 minutes, the assay strip is 
inserted into the Triage meter and read. The BNP value is displayed on the screen. We 
transported 2 BNP Triage meters from London to Cagliari, Sardinia for each of the 3 visits. The 
BNP assay strips were obtained from the UK Biosite headquarters in Belfast. The assay strips 
were flown out on dry ice (to maintain optimum temperature) to the Ospendale Micocittemi 
where the study took place. Upon arrival they were refrigerated and kept between 2 to 8 degrees 
celsius 
 
5.3.2 Calibration & Validation Tests 
Control assays were performed on both triage meters prior to each Cagliari visit and with each 
new batch of BNP test devices. Daily quality control tests were performed with the simulator. 
Some samples were analysed twice in the same triage meter, others samples were analysed twice 
in different triage meters for consistency of results. 
 
5.3.3 BNP Levels Before And After Blood Transfusion 
We planned to look at the effect of blood transfusion on levels of BNP. We proposed that 
although in some cases cardiac iron infiltration may not have affected the BNP level at rest it 
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would cause some subtle cardiac dysfunction. A volume challenge, such as with planned blood 
transfusions may cause a transient elevation in BNP levels, therefore unmasking evidence of 
cardiac dysfunction. The half life of BNP is 18 minutes. We took blood for BNP assays 
immediately at the end of the blood transfusion, then after 18 minutes and each 18 minutes 
thereafter for 5 half lives. A further assay was taken at 24 hours. 
 
5.4  CARDIAC MAGNETIC RESONANCE IMAGING PROTOCOL  
CMR was performed at baseline and after 6 and 12 months of treatment. Myocardial T2* was 
assessed with the use of a single breath-hold multiecho technique that can be completed in 5 
minutes, as previously described (251). In brief, a single 10-mm-thick short-axis midventricular 
slice of the LV was acquired at 8 echo times (2.6 to 16.7 ms, with 2.02-ms increments) with 
standard shimming in a single breath-hold. For analysis, a full-thickness region of interest was 
chosen in the LV septum. The signal intensity of this region was measured for each image with 
the use of in-house designed software (CMR tools, Cardiovascular Imaging Solutions, London, 
UK). Ventricular volumes were determined with the use of steady state free precession cines, 
with contiguous short-axis slices from base to apex, as previously described (252). Ventricular 
volumes were also analyzed with the use of CMR tools.  
 
5.5  STATISTICS & ANALYSIS  
SPSS v 14 was used for all statistical analysis. A P value of <0.05 was deemed statistically 
significant. We used Spearmans rank correlation, unpaired T test for comparisons between 
groups and paired T test for comparisons across time. The baseline cohort data was analysed to 
determine which standard parameters correlated well with the cardiac T2* from MRI. The 
baseline cohort were divided into groups according to the cardiac T2* score as detailed in 
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sections 2.11 and 5.1.2. Echo parameters were compared across groups to establish which 
parameters could help differentiate the severity of cardiac iron loading. At the end of 12 months 
the patients codes were unlocked to reveal treatment allocations. The treatment groups were 
compared across the study duration to establish which echo measures improve with 
improvement in cardiac T2*. These measures could be useful for risk stratification in countries 
where cardiac T2* MRI is not widely available. All echo measures were made with the 
observers blinded to which therapies each patient received. Only at the stage when comparisons 
were made for the trial group across the 12 month treatment period were the codes unlocked and 
the observers able to identify which patients received the combination therapy and which 






CHAPTER 6: RESULTS 
6.1  OVERALL STUDY POPULATION  
All 167 patients underwent cardiac MRI with T2* assessment (75). 166 out of the same 167 
patients underwent TTE evaluation with full tissue Doppler data acquisition. The 
echocardiograms were performed on the same day within hours of the cardiac MRI scan with 
the exception of 2 patients who had the echocardiograms performed 1 week after the initial T2* 
cardiac MRI scan, upon their return for full MRI with volume assessment. Echo reports were 
produced and kept in the patients file for reference and use by the local haematologists (Baseline 
Echo Reports on the appendix CD). The raw data from the tissue Doppler analysis for each 
patient is included on the appendix CD (Baseline TDI data). In addition all 167 patients had 
blood taken for BNP levels. The full data set for the baseline data is included in appendix A. 
Summary characteristics for the baseline 167 patients are shown below (Table 6.1 & Figures 6.1 
– 6.3). 
 Range 
Age Range 18-41 years 
Male 75 (45%) 
Female 92 (55%) 
Ferritin Range 60-8640ug/l 
T2* Range 2.8-84.7ms 
MRI EF 28-84% 
LVdD 3.6-6.0cm 
Echo M mode EF 25-78% 
Echo 4 Ch EF 24-75% 
LA size 9.5-26cm2 
Table 6.1 
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Out of the 167 screened the group were broken down by T2* categories. 108 patients (65%) had 
a T2* <20ms indicating significant cardiac iron. Of these, 22 (13% of total screened) had severe 
cardiac iron, i.e. T2*<8ms, 37 had moderate cardiac iron (T2* 8-12ms) and 49 had mild cardiac 
iron (T2* 12-20ms). The remaining 59 had T2*>20ms indicating no cardiac iron (Figure 6.2). 
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6.2 BNP RESULTS AT BASELINE  
BNP results were compared with T2*. Although there was a significant relationship between 
BNP levels and T2* this was largely driven by the 5 BNP values that were >100pg/ml. (Figure 
6.4). All 5 patients with BNP > 100pg/ml (the usual level, beyond which possibility if heart 
failure is considered) had significant cardiac iron and 3 of these had significant left ventricular 
impairment (252). A BNP of >100 pg/ml should, therefore,  highlight the need for further 
cardiac iron assessment with T2* MRI and left ventricular function with TTE. Intensification of 
iron chelation and treatment for heart failure should follow. However, the sensitivity of just 
4.6% for a high BNP level precludes its use as a screening test for cardiac iron. Of the 25 
patients who had a low BNP level of <5pg/ml, 13 had T2* >20ms. Although the remaining 12 
had varying degrees of iron loading, only 1 had a T2*<8ms and all of these patients had 
preserved ejection fraction from cardiac MRI. A BNP level of less than 5pg/ml had a negative 





Figure 6.4 Although the correlation is significant due to the 5 high values, BNP has no 
meaningful relationship with cardiac T2* (2).  
 
On echo assessment those with BNP levels <5pg/ml had ejection fractions greater than 55% by 
either M mode or 4 chamber Simpsons technique in all but 1 patient. Using a BNP cut off value 
of <5pg/ml to identify those without LV dysfunction (i.e. an echo LVEF of >55%) gave a 
positive predictive value of 96% with only 1 (4 %) false positive. Overall a BNP level of 
<5pg/ml is strongly suggestive of preserved LV systolic function (96% chance) and although it 
is relatively unhelpful regarding the degree of cardiac iron loading it is suggestive against severe 
cardiac iron load (only a 4% chance of severe cardiac iron with a BNP of <5pg/ml). Overall, 
although there was a correlation between BNP and TTE EF, this was largely driven by a few 




Figure 6.5 Although the correlation is again significant there is no meaningful relationship 
between BNP and echo 4 chamber ejection fraction. 
 
6.3 STANDARD ECHO MARKERS AND CORRELATION WITH CARDIAC T2* 
We looked to see if any of the standard TTE variables correlated with cardiac T2* and hence 
could be used to identify those with significant cardiac iron at risk of cardiac decompensation.  
An EF <55% (17.4% of patients, n=29) had a positive predictive value of 90% for a T2* 
of <20ms. If the echo ejection fraction cut off is lowered to 50% then all patients with an EF 
below this threshold had significant cardiac iron loading (Figure 6.6). However the vast majority 
of those with cardiac iron i.e. MRI T2*<20ms had preserved EF by TTE. It is this group that 
represent the greatest challenge as a proportion of these patients may be falsely reassured by the 
preserved function on echo and yet may still be at significant risk of cardiac decompensation 

























Figure 6.6 Cardiac iron is present when TTE EF falls below 50% 
 
The graph demonstrated in figure 6.6 is very similar to the relationship between cardiac MRI EF 
and T2*, (75;253), although with MRI a higher ejection fraction of 56% is used to represent 
normal systolic function. 94 patients had some degree of valve dysfunction. Mostly this was 
trivial regurgitant lesions occurring in 66 patients, mostly affecting the tricuspid and mitral 
valves. Of the 28 patients in which there was either mild or moderate TR or MR, 22 had cardiac 
iron present giving a positive predictive value of 80% for cardiac iron. Pulmonary artery 
pressures were >25mmhg in 12 patients (7.2%) of which 8 had iron. LV dilatation was observed 





Abnormalities on transthoracic echocardiography occur frequently in a population receiving 
conventional best care. However, with the exception of reduced left ventricular function which 
had a positive predictive value of 90% for iron the other parameters analysed had poor ability in 
predicting cardiac iron load. 
 
Diastolic function assessed by transmitral E:A ratio did not correlate with cardiac T2*. There 
was no significant difference in the mean E:A ratio of those with severe cardiac iron compared 




Figure 6.7 No correlation between E:A as measure of diastolic function and cardiac T2* 
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Figure 6.8 No difference in mean E:A ratio between groups with severe and no iron 
 
6.4 COMPARISON BETWEEN EJECTION FRACTION CALCULATED FROM TRANS THORACIC 
ECHOCARDIOGRAPHY & FROM CARDIAC MRI 
 
TTE EF’s above 50% occurred throughout the spectrum of iron loading. However an EF of 
<50% only occurred in patients with a T2* of <20ms indicating significant cardiac iron loading.  
These results are consistent with previous studies comparing MRI EF with T2*. In addition to 
cardiac function assessed by MRI EF, 97 patients had TTE EF by M mode & 89 by 4 chamber 
Simpsons (Figures 6.9 & 6.10). Both TTE measures of EF had a significant correlation with the 





















Figure 6.9 (above) & 6.10 (below). There is a strong correlation between EF calculated 
from cardiac MRI and from M mode or 4 chamber Simpsons on TTE. 
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6.5 ADVANCED ECHO MARKERS AND CORRELATION WITH CARDIAC T2* 
6.5.1 Systolic Tissue Doppler Velocities 
6.5.1.1 In The Baseline Cohort 
We compared the result from tissue Doppler techniques to see if they correlated with cardiac 
T2* measurements. The mean systolic tissue velocity from the 6 regions was compared between 
the group with no cardiac iron and the group with severe cardiac iron. The mean systolic 
velocities were significantly different with a p value <0.05 in both the basal and mid segments 
of both the septum and RV free wall. The basal septal velocities were 4.78 cm/s (+/- 0.90 
(standard deviation)) in the severe iron group versus 5.76 cm/s (+/- 1.18) in the no iron group, 
p<0.001 (Figure 6.11). The corresponding values for the mid septum were 3.31 cm/s (+/- 0.85) 
versus 3.92 cm/s (+/- 1.19), p=0.035 (Figure 6.12), for the basal RV wall were 9.11 cm/s (+/- 
2.50) versus 11.50 cm/s (+/- 2.39) p=0.000 (Figure 6.13) and the mid RV wall were 5.39 cm/s 
(+/- 2.30) versus 7.10 cm/s (+/- 2.93), p=0.023 (Figure 6.14). There was no significant 
difference in systolic velocities in the lateral wall between the groups with severe iron and those 





Figure 6.11 Significantly lower mean basal septum systolic velocities in severe group 
 
Figure 6.12 Significantly lower mean mid septum systolic velocities in severe group   
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Figure 6.13 Significantly lower mean basal RV systolic velocities in severe group  
 
Figure 6.14 Significantly lower mean mid RV systolic velocities in severe group  
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The systolic velocities did not differ significantly between the groups with mild or moderate iron 
loading compared to those with normal T2*(no significant cardiac iron) in any of the 6 regions 
analysed. 
 
In normal subjects peak systolic velocities show a gradual decline from the basal segments 
through the mid sections to the apical regions. This reflects greater movement and velocity of 
movement at the base of the heart compared with the apex which remains relatively fixed during 
the cardiac cycle. In most patients the tissue Doppler velocity curves demonstrated the expected 
reduction in systolic velocities in the mid wall compared with the basal wall (Figure 6.15). 
Occasionally the tissue Doppler velocities in the mid wall were higher than in the basal wall 
segments. The patients in whom this occurred were not always the patients with significant 









Figure 6.16 IG01 Abnormal tissue Doppler with higher velocities in mid wall than base 
 
6.5.1.2 Baseline Cohort With EF of >55% On TTE 
In those with normal ejection fraction from transthoracic echocardiography, tissue systolic 
velocities can be useful to determine if there is severe cardiac iron present compared with no 
cardiac iron. When the systolic velocities for the basal septum are compared, those with severe 
cardiac iron have significantly lower velocities than those with no cardiac iron 5.09 cm/s (+/- 
0.89) versus 5.90 cm/s +/- (1.14) p=0.028, (Figure 6.17). Similar significantly lower basal RV 
systolic velocities were found in those with normal EF by TTE  and severe cardiac iron loading 
versus those with no cardiac iron. 10.04cm/s (+/- 2.74) versus 11.65 cm/s (+/- 2.38) p=0.05, 
(Figure 6.18).   
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Figure 6.17 Significantly lower mean basal septum systolic velocities in severe group  
 
Figure 6.18 Significantly lower mean basal RV systolic velocities in severe group  
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6.5.2 Diastolic Tissue Doppler Velocities 
Similar results were obtained for diastolic tissue Doppler velocities, Ea (early diastolic filling) 
and Aa (atrial systole). The mean early diastolic velocities were significantly lower in the group 
with severe cardiac iron compared to those with no cardiac iron in the basal septum -7.07cm/s 
(+/- 1.71) versus -8.43 cm/s (+/-1.71), p=0.002 (Figure 6.19), mid septum -6.54cm/s (+/- 1.90) 
versus -7.68cm/s (+/-2.21), p=0.04 and the basal RV wall -9.61cm/s (+/- 2.86) versus -
11.92cm/s (+/- 2.45), p=0.001. The mean early diastolic velocities in the lateral wall were not 
significantly different in those with severe iron compared to those with no cardiac iron. 
Interestingly the mean diastolic velocities during atrial systole (Aa) were significantly lower in 
those with severe iron compared to those with no cardiac iron. This significant difference was 
observed in both the basal and mid sections of all 3 walls analysed (Figures 6.20, 6.21 & 6.22).  
The mean diastolic velocities did not show any significant differences when compared across 








Figure 6.20 Significantly higher basal septum Aa velocities in the no iron group 
 
Figure 6.21 Significantly higher basal lateral Aa velocities in the no iron group 
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 T2* N Mean Std Dev Std Error Mean P Value  
BSAa Severe 20 -3.703 1.628 0.364 0.001  
 None 57 -5.305 1.766 0.234   
MSAa Severe 19 -2.362 1.023 0.234 0.006  
 None 57 -3.180 1.191 0.157   
BLAa Severe 21 -2.896 1.585 0.346 0.000  
 None 55 -4.997 2.072 0.279   
MLAa Severe 21 -2.051 1.166 0.254 0.001  
 None 55 -3.406 2.096 0.282   
BRVAa Severe 19 -7.700 3.365 0.772 0.021  
 None 50 -9,854 3.010 0.425   
MRVAa Severe 18 -3.306 4.126 0.972 0.047  
 None 51 -5.311 3.418 0.478   
 
Figure 6.22 Significantly lower myocardial velocities (cm/s) during atrial systole in the 
severe versus no cardiac iron groups (BS = basal septum, MS = mid septum, BL = basal 
lateral, MS = mid lateral, BRV = basal RV, MRV = mid RV). 
 
E/E’ (E/Ea) was calculated in the 6 regions and compared between the group with severe iron 
and the group with no cardiac iron loading. The E/E’ ratio was higher in the severe iron group in 
the basal septum 14.9 +/- 4.5 versus 12.5 +/- 3.2 in the group without cardiac iron. 
 
6.5.3 Strain 
Strain parameters were calculated for the 6 regions. We measured the strain at the closure of the 
aortic valve, peak strain, and noted if this occurred before or after the closure of the aortic valve 
& early diastolic strain, occurring shortly after mitral valve opening (Figure 6.23). The strain 
curves were more variable than the tissue Doppler curves with a number of measures not 
obtained due to poor curves or marked variation between the curves obtained from the 3 cardiac 
cycles (Figure 6.24). Frequently there was not a clearly identifiable peak for early diastolic 
strain. In addition, post systolic peak strain was observed, i.e. the peak strain occurring after the 
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aortic valve closure, in some cases (Figure 6.25). Post systolic strain indicates ongoing LV 




Figure 6.23 Peak strain occurring at aortic valve closure and a separate peak for early 








Figure 6.24 Lack of consistency or reproducibility of strain curves. 
 
Occurrence of post systolic peak strain did not always correlate with the presence or severity of 
cardiac iron loading. In some hearts without cardiac iron post systolic peak strain also occurred 
(patient AL04 – T2* = 20.6ms, strain curve similar to Figure 6.25). In addition, within a patient 
the presence of post systolic peak strain was not constant, for example the peak strain may occur 
after the aortic valve closure for the septum but before the aortic valve closure for the lateral 
wall. In some cases the strain curves were positive (Figure 6.26), again this abnormality did not 












Figure 6.26 – (CA17) Positive strain pattern in the basal RV wall 
 
 T2* N Mean Std Dev P Value  
BS Strain  Severe 21 -12.067 7.253 0.049  
AVC None 54 -16.191 8.272   
MS Strain Severe 21 -13.087 6.065 0.022  
AVC None 57 -17.892 8.623   
BL Strain Severe 22 -6.244 7.026 0.468  
AVC None 51 -8.453 13.378   
ML Strain Severe 21 -8.456 4.913 0.011  
AVC None 54 -12.104 5.431   
BRV Strain Severe 20 -18.023 8.335 0.547  
AVC None 55 -20.629 18.544   
MRV Strain Severe 19 -20.870 14.016 0.472  
AVC None 52 -23.932 16.390   
 
Figure 6.27 - Strain at AVC – Severe iron versus no cardiac iron 
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Strain at aortic valve closure was significantly lower in the severe iron group in the basal and 
mid septum as well as the mid lateral walls (Figure 6.27). It is difficult to be sure if strain 
parameters are not helpful in this population or whether any useful correlations were masked 
due to the variability and inconsistency of the strain curves and data obtained. Maximum strain 
(Figure 6.28) and early diastolic strain (Figure 6.29) did not correlate with T2* and did not 
significantly differ between the groups with severe cardiac iron loading and no cardiac iron 
loading. Although strain at aortic valve closure was significantly lower in some regions in the 
severe cardiac iron group the standard deviations were very large. The large variability, poor 
reproducibility and inconsistency of the strain parameters is likely to have contributed to the 
wide standard deviations and masked any differences that may be present.  
 
 
 T2* N Mean Std Dev P Value  
BS Strain Severe 18 -16.258 6.495 0.094  
Max None 51 -20.201 9.046   
MS Strain Severe 15 -14.374 12.678 0.046  
Max None 50 -19.675 7.377   
BL Strain Severe 22 -8.135 8.093 0.805  
Max None 46 -8.996 14.684   
ML Strain Severe 19 -14.799 24.106 0.640  
Max None 49 -13.025 7.170   
BRV Strain Severe 18 -20.292 8.440 0.387  
Max None 49 -24.362 19.073   
MRV Strain Severe 14 -18.938 15.796 0.434  
Max  None 42 -23.319 18.662   
 







 T2* N Mean Std Dev P Value  
BS ED Severe 16 -8.707 5.881 0.656  
Strain None 33 -9.674 7.584   
MS ED Severe 14 -4.003 7.762 0.324  
Strain None 38 -5.864 5.212   
BL ED Severe 15 -4.959 4.096 0.743  
Strain None 29 -5.503 5.637   
ML ED Severe 15 -0.509 3.119 0.091  
Strain None 43 -2.674 4.499   
BRV ED Severe 14 -6.586 5.842 0.400  
Strain None 29 -8.360 6.658   
MRV ED Severe 12 -8.432 6.461 0.589  
Strain None 26 -9.718 6.894   
 
Figure 6.29 Early Diastolic Strain – Severe iron versus no cardiac iron 
 
 
6.5.4 Strain Rate 
The strain rate was measured as a peak occurring between aortic valve opening and closure.  
The strain rate curves were often quite reproducible from beat to beat (Figure 6.30). The curves 
were sometimes positive (Figure 6.31). Strain rate did not correlate with presence or severity of 








Figure 6.31 (CA17) Positive strain rate pattern in the basal RV wall 
 
 T2* N Mean Std Dev P Value  
BS Strain Severe 20 -0.917 0.497 0.051  
Rate None 57 -1.270 0.739   
MS Strain Severe 21 -1.157 0.344 0.146  
Rate None 57 -1.380 0.659   
BL Strain Severe 21 -0.640 0.568 0.291  
Rate None 55 -0.876 0.952   
ML Strain Severe 22 -0.624 0.553 0.149  
Rate None 56 -0.812 0.497   
BRV Strain Severe 20 -1.314 0.591 0.155  
Rate None 55 -1.798 1.457   
MRV Strain Severe 19 -1.368 0.807 0.314  
Rate  None 53 -1.694 1.308   
 
Figure 6.32 Strain Rate – Severe iron versus no cardiac iron 
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6.5.5 Tissue Tracking 
The tissue tracking function allowed the visualization of longitudinal motion in each myocardial 
segment. The function was applied to the 6 regions of interest and the peak longitudinal motion 
measured. The function colour codes different regions according to the amount of longitudinal 
motion. In the normal subject a gradual reduction in longitudinal motion is seen from the basal 
segment to the mid wall to the apex, the so called basal - apical gradient. With systolic 
impairment a reduction in maximum longitudinal displacement is seen with a reduced basal 
apical gradient. In most subjects a typical basal apical gradient of reducing longitudinal 
displacement was seen (Figure 6.33).  
 
 
Figure 6.33 Typical gradient of longitudinal displacement from the base to apex 
 91
When compared to those with no cardiac iron, those with severe iron had reduced tissue 
tracking, indicative of reduced longitudinal motion in the basal and mid sections of both the 
septum and right ventricular free wall (Figures 6.34, 6.35 & 6.36).  
 
 T2* N Mean Std Dev P Value  
BS TT Severe 21 8.295 2.600 0.001  
 None 57 10.417 2.287   
MS TT Severe 21 5.553 2.130 0.021  
 None 57 6.754 1.953   
BL TT Severe 22 8.772 2.282 0.119  
 None 56 9.994 3.332   
ML TT Severe 22 6.013 1.701 0.719  
 None 56 6.221 2.485   
BRV TT Severe 20 16.519 5.989 0.001  
 None 55 21.254 4.883   
MRV TT Severe 20 8.578 4.240 0.018  
 None 53 11.762 5.272   
 
Figure 6.34 Tissue Tracking (Longitudinal Motion) Severe iron versus no cardiac iron 
 
The longitudinal motion was not significantly different in the lateral wall. The longitudinal 
displacement obtained from the right ventricular free wall was consistently higher than the 
values obtained from either the septum or the lateral wall. 
 
6.5.6 Reproducibility Studies 
A number of analyses were performed multiple times by the same observer. The intraobserver 
variability for the TDI parameters was acceptable at 4% for Sa velocities, 3% for Ea velocities, 





Figure 6.35 Lower mean longitudinal motion of basal septum in the severe iron group 
 
Figure 6.36 Lower mean longitudinal motion of basal RV in severe iron group 
 93
6.6 GROUP WITH CARDIAC IRON PRESENT (T2* <20MS) 
We analysed the group with cardiac iron present, (T2*<20ms) to see if tissue Doppler 
parameters were significantly different in those with normal EF by echocardiography (EF 
>55%), compared to those with impaired ventricular function, EF < 54%. We demonstrated 
some significant differences in those with iron and impaired ejection fractions compared to 
those with iron and preserved systolic function. Tissue systolic velocities were significantly 
lower in the septum and RV free walls (Figure 6.37) as were the early and late diastolic 
velocities (Figure 6.38, 6.39). Again, the late diastolic velocities were reduced in those with iron 
and reduced EF, although not in all 6 regions. 
 
 EF N Mean Std Dev P Value  
BS Sa <54% 21 4.252 1.025 0.000  
 >55% 84 5.308 1.077   
MS Sa <54% 21 3.098 0.906 0.003  
 >55% 84 3.813 0.959   
BL Sa <54% 22 5.437 1.919 0.861  
 >55% 83 5.508 1.641   
ML Sa <54% 21 4.862 2.249 0.627  
 >55% 84 4.621 1.995   
BRV Sa <54% 21 7.959 4.185 0.000  
 >55% 83 11.040 2.202   
MRV Sa <54% 21 5.304 2.148 0.003  
 >55% 81 7.033 2.384   
 
Figure 6.37 Significantly lower mean systolic velocities in the basal & mid septum & RV in 




 EF N Mean Std Dev P Value  
BS Ea  <54% 21 -6.099 1.466 0.000  
 >55% 84 -7.630 1.622   
MS Ea <54% 21 -5.434 1.986 0.002  
 >55% 83 -6.953 1.987   
BL Ea <54% 22 -10.196 2.150 0.364  
 >55% 83 -10.692 2.302   
ML Ea <54% 22 -8.682 1.773 0.829  
 >55% 81 -8.820 2.829   
BRV Ea <54% 21 -9.143 2.639 0.022  
 >55% 80 -10.687 2.718   
MRV Ea <54% 21 -5.987 2.506 0.090  
 >55% 77 -7.049 2.523   
 
Figure 6.38 Significantly lower mean early diastolic velocities in the basal & mid septum & 
basal RV in those with iron and reduced EF. 
 
Although there were some significant differences in strain these were very variable and 
inconsistent between which strain was measured (Figures 6.40, 6.41 & 6.42). Strain rate was 
significantly lower in those with iron and reduced EF in the lateral wall (Figure 6.43). 
Longitudinal motion in the septum and RV (Figure 6.44) was significantly lower in patients with 








 EF N Mean Std Dev P Value  
BS Aa <54% 19 -3.795 1.443 0.083  
 >55% 84 -4.611 1.910   
MS Aa <54% 19 -2.362 0.911 0.013  
 >55% 83 -3.100 1.198   
BL Aa <54% 20 -2.548 1.454 0.016  
 >55% 82 -3.711 1.995   
ML Aa <54% 20 -1.725 1.244 0.025  
 >55% 80 -2.639 1.679   
BRV Aa <54% 19 -7.740 2.888 0.028  
 >55% 83 -9.432 3.008   
MRV Aa <54% 19 -3.982 3.221 0.081  
 >55% 80 -5.582 3.619   
 
Figure 6.39 Significantly lower mean late diastolic velocities in mid septum, basal and mid 
lateral and basal RV free wall in those with iron and reduced EF. 
 
 EF N Mean Std Dev P Value  
BS Strain  <54% 20 -11.443 7.857 0.077  
AVC >55% 79 -15.354 8.956   
MS Strain <54% 21 -11.641 6.808 0.001  
AVC >55% 81 -16.936 6.176   
BL Strain <54% 19 -4.282 12.844 0.150  
AVC >55% 77 -8.847 12.134   
ML Strain <54% 20 -8.477 5.334 0.071  
AVC >55% 77 -10.917 5.325   
BRV Strain <54% 19 -15.594 16.748 0.63  
AVC >55% 82 -23.012 15.179   
MRV Strain <54% 20 -21.454 15.016 0.128  
AVC >55% 78 -26.539 12.539   
 
Figure 6.40 Significantly lower strain at the AVC in the mid septum in those with iron and 
reduced EF. 
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 EF N Mean Std Dev P Value  
BS Strain <54% 16 -16.064 5,923 0.195  
Max >55% 73 -19.323 9.572   
MS Strain <54% 19 -10.284 5.774 0.353  
Max >55% 74 -13.124 12.886   
BL Strain <54% 18 -5.196 14.752 0.123  
Max >55% 75 -10.867 13.667   
ML Strain <54% 19 -10.284 5.774 0.353  
Max >55% 74 -13.125 12.886   
BRV Strain <54% 20 -17.296 17.349 0.033  
Max >55% 79 -24.106 11.131   
MRV Strain <54% 19 -20.752 15.335 0.054  
Max  >55% 74 -27.391 12.681   
 
Figure 6.41 Significantly lower maximum strain in the basal RV in those with iron and 
reduced EF. 
 
 EF N Mean Std Dev P Value  
BS ED <54% 8 -4.877 5.084 0.017  
Strain >55% 45 -10.919 6.544   
MS ED <54% 7 -1.818 4.068 0.075  
Strain >55% 45 -6.868 7.126   
BL ED <54% 8 -4.173 3.568 0.275  
Strain >55% 45 -6.212 4.987   
ML ED <54% 9 -1.670 3.265 0.737  
Strain >55% 56 -1.330 2.733   
BRV ED <54% 7 -3.840 5.386 0.046  
Strain >55% 44 -9.513 6.990   
MRV ED <54% 6 -9.947 4.559 0.811  
Strain >55% 29 -9.040 8.911   
 
Figure 6.42 Significantly lower mean ED Strain in the basal septum & basal RV in those 
with iron and reduced EF. 
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 EF N Mean Std Dev P Value  
BS Strain <54% 21 -1.106 0.696 0.693  
Rate >55% 83 -1.167 0.605   
MS Strain <54% 22 -0.583 0.526 0.043  
Rate >55% 80 -0.788 0.381   
BL Strain <54% 21 -0.371 0.912 0.042  
Rate >55% 82 -0.836 0.927   
ML Strain <54% 22 -0.583 0.526 0.043  
Rate >55% 80 -0.788 0.381   
BRV Strain <54% 21 -1.297 1.283 0.478  
Rate >55% 83 -1.484 1.014   
MRV Strain <54% 21 -1.343 1.020 0.072  
Rate  >55% 79 -1.784 0.980   
 
Figure 6.43 Significantly lower mean strain rate in the mid septum and basal and mid 
lateral wall in those with iron and reduced EF. 
 
 EF N Mean Std Dev P Value  
BS TT <54% 21 6.852 2.397 0.000  
 >55% 84 9.628 2.086   
MS TT <54% 21 4.597 1.954 0.004  
 >55% 84 6.336 2.498   
BL TT <54% 22 8.247 2.177 0.135  
 >55% 83 9.112 2.447   
ML TT <54% 22 5.865 2.206 0.844  
 >55% 81 5.751 2.463   
BRV TT <54% 21 15.720 4.929 0.000  
 >55% 83 20.617 4.495   
MRV TT <54% 21 8.222 4.679 0.002  
 >55% 80 11.445 4.034   
 
Figure 6.44 Significantly lower longitudinal motion in the basal and mid septum and RV in 
those with iron and reduced EF. 
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6.9 SEVERE IRON LOADING COHORT  
6.7.1. Severe Group Characteristics  
This group were excluded from randomisation and were treated with best medical therapy at the 
discretion of their local haematologists. Of 22 patients in the severe cardiac iron group, 15 
received both Desferrioxamine and Deferiprone chelation therapy. They were followed and had 
repeat MRI and TTE with tissue Doppler studies at 6 and 12 months. There were no deaths or 
new cardiovascular complications. The baseline characteristics are shown below (254). 
 
 
From baseline to 12 months the myocardial T2* improved (5.7 ±0.98ms to 7.9 ±2.47ms; 





6.7.2. Standard Echo Data  
The ejection fraction on echo increased significantly over the 12 months of intensive chelation 
therapy. The M mode EF increased from 49.17 +/- 10.54% to 62.17 +/- 6.10%; p=0.001 (Figure 
45) and the 4 chamber EF increased from 52.73 +/- 11.18% to 62.60 +/- 4.35%; p=0.016 (Figure 
46).  
 
Figure 6.45 M Mode EF in severe group improves after 12 months intensive chelation 
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Figure 6.46 – 4 Ch EF improves in the severe group after 12 months intensive chelation 
 
6.7.3 Systolic Tissue Doppler Velocities 
There was a parallel improvement in systolic tissue Doppler velocities. Mean systolic velocity 
increased significantly in the septum and RV free wall. Velocities improved significantly in the 
basal septum (4.81 ± 1.04cm/s to 5.46 ± 0.74cm/s p=0.015, Figure 6.47), mid septum (3.40 ± 
0.71cm/s to 4.10 ± 0.65cm/s p=0.007), basal RV free wall (9.11 ± 2.36cm/s to 10.73 ± 1.84cm/s 
p=0.006, Figure 6.48) & mid RV free wall (5.57 ± 2.28cm/s to 10.73 ± 1.85cm/s p=0.000.  
Changes in systolic velocities from the lateral wall did not achieve statistical significance 
(Figure 6.49).  
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Figure 6.49 No significant improvement in mean mid lateral systolic velocity after 12 
months intensive chelation 
 
6.7.4 Diastolic Tissue Doppler Velocities 
The mean Ea improved significantly across time in the mid septum, basal lateral and basal RV 
walls (Figure 6.50) and the mean Aa improved significantly in the basal lateral, mid lateral and 






 Time N Mean Std Dev P Value  
BS Ea Baseline 16 -6.935 1.843 0.069  
 12 Months 16 -7.758 1.472   
MS EA Baseline 16 -6.444 1.923 0.034  
 12 Months 16 -7.454 1.534   
BL EA Baseline 17 -10.276 2.202 0.006  
 12 Months 17 -12.164 2.744   
ML Ea Baseline 17 -8.635 2.267 0.050  
 12 Months 17 -9.938 2.687   
BRV Ea Baseline 15 -9.739 2.717 0.015  
 12 Months 15 -11.460 2.153   
MRV Ea Baseline  15 -7.134 3.640 0.095  
 12 Months 15 -8.740 2.455   
 




 Time N Mean Std Dev P Value  
BS Aa Baseline 15 -3.628 1.570 0.374  
 12 Months 15 -3.877 1.254   
MS Aa Baseline 14 -2.257 1.070 0.271  
 12 Months 14 -2.579 1.094   
BL Aa Baseline 16 -2.752 1.609 0.009  
 12 Months 16 -3.801 1.668   
ML Aa Baseline 16 -1.969 1.166 0.021  
 12 Months 16 -2.872 1.525   
BRV Aa Baseline 13 -7.876 3.982 0.174  
 12 Months 13 -9.456 2.344   
MRV Aa Baseline 12 -4.621 3.004 0.017  
 12 Months 12 -7.132 2.761   
 









Strain at the AVC was not significantly different after 12 months intensive chelation in the 
severe group. The result from the basal RV reached significance although this was heavily 
influenced by 4 positive strain curves in the severe group at 12 months (Figure 6.52). 
 
 Time N Mean Std Dev P Value  
BS Strain Baseline 15 -12.712 7.183 0.354  
AVC 12 Months 15 -14.351 7.882   
MS Strain Baseline 16 -12.884 6.105 0.079  
AVC 12 Months 16 -16.018 5.701   
BL Strain Baseline 14 -4.178 6.265 0.410  
AVC 12 Months 14 -6.842 8.380   
ML Strain Baseline 16 -8.643 4.935 0.812  
AVC 12 Months 16 -9.026 4.719   
BRV Strain Baseline 14 -19.470 8.392 0.002  
AVC 12 Months 14 -1.545 14.360   
MRV Strain Baseline 14 -22.003 13.983 0.272  
AVC 12 Months 14 -28.827 16.618   
 
Figure 6.52 Strain at the AVC in the severe group after 12 months intensive chelation 
 
Neither maximum strain (Figure 6.53) nor early diastolic strain (Figure 6.54) had any significant 
differences in any of the 6 regions analysed following 12 months intensive chelation. Strain rate 
was significantly different in the basal RV after 12 months although again this was due to 
positive strain rate curves in a number of patients at 12 months (Figure 6.55). It is not clear why 
there were more positive strain and strain rate curves in the severe group after 12 months 




 Time N Mean Std Dev P Value  
BS Strain Baseline 12 -16.982 5.041 0.247  
Max 12 Months 12 -19.482 4.575   
MS Strain Baseline 11 -17.142 12.088 0.774  
Max 12 Months 11 -15.733 9.063   
BL Strain Baseline 11 -3.794 8.234 0.266  
Max 12 Months 11 -8.833 9.741   
ML Strain Baseline 14 -16.791 27.891 0.378  
Max 12 Months 14 -9.610 5.489   
BRV Strain Baseline 9 -19.741 9.799 0.054  
Max 12 Months 9 -2.778 18.345   
MRV Strain Baseline 11 -21.567 15.171 0.108  
Max 12 Months 11 -32.479 10.928   
 
Figure 6.53 Maximum strain in the severe group after 12 months intensive chelation 
 
 Time N Mean Std Dev P Value  
BS ED Baseline 6 -9.700 2.457 0.064  
Strain 12 Months 6 -13.256 4.584   
MS ED Baseline 7 -3.401 9.014 0.187  
Strain 12 Months 7 -9.459 6.791   
BL ED Baseline 3 -2.555 4.976 0.955  
Strain 12 Months 3 -2.269 5.419   
ML ED Baseline 8 -1.435 3.309 0.747  
Strain 12 Months 8 -0.935 2.056   
BRV ED Baseline 3 -8.642 5.394 0.901  
Strain 12 Months 3 -7.885 4.020   
MRV ED Baseline 1     
Strain 12 Months 1     
 





 Time N Mean Std Dev P Value  
BS SR Baseline 15 -1.028 0.371 0.228  
 12 Months 15 -1.185 0.519   
MS SR Baseline 16 -1.134 0.339 0.543  
 12 Months 16 -1.217 0.426   
BL SR Baseline 14 -0.581 0.570 0.308  
 12 Months 14 -0.793 0.395   
ML SR Baseline 16 -0.560 0.592 0.373  
 12 Months 16 -0.733 0.490   
BRV SR Baseline 12 -1.387 0.679 0.021  
 12 Months 12 -0.514 1.072   
MRV SR Baseline 15 -1.522 0.704 0.083  
 12 Months 15 -2.104 1.100   
 
Figure 6.55 Strain rate in the severe group after 12 months intensive chelation 
 
 
6.7.6 Tissue Tracking 
The mean tissue tracking increased from baseline to 12 months (Figure 6.56) in all segments 
although the increases were significant only in the mid walls and not the basal segments. 
 Time N Mean Std Dev P Value  
BS TT Baseline 16 8.152 2.870 0.901  
 12 Months 16 8.365 5.757   
MS TT Baseline 15 5.247 2.182 0.013  
 12 Months 15 6.821 1.950   
BL TT Baseline 17 8.666 2.565 0.956  
 12 Months 17 8.757 6.268   
ML TT Baseline 17 5.912 1.822 0.007  
 12 Months 17 7.290 2.134   
BRV TT Baseline 15 16.130 6.406 0.059  
 12 Months 15 19.764 4.441   
MRV TT Baseline 15 8.556 4.664 0.008  
 12 Months 15 13.030 4.078   
 
Figure 6.56 Tissue tracking in the severe group after 12 months intensive chelation 
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6.10 TWELVE MONTH RESULTS FOR RANDOMISED COHORT 
6.8.1. Cohort Characteristics at baseline 
 Combined  Deferoxamine P value 
Number randomized 32 (49%) 33 (51%) na 
Age (years) 28.8 ±4.2 28.7 ±5.3 0.9 







Body Surface Area (m2) 1.53 ±0.15 1.56 ±0.16 0.5 






Myocardial T2* (ms) [normal >20] 
Liver T2* (ms) [normal >19] 
LV end diastolic volume (mL) [M:77-195, F:52-141] 
LV end systolic volume (mL) [M:19-72, F:13-51] 




















Transfusional red blood cell input (mL/kg/year) 
Hemoglobin (g/L) 
Total white blood cell count (x109/L) 

































Serum ferritin (µg/L) [M: 5-104, F: 4-254 ] 
Alanine transaminase (IU/L) [5-35 ] 
BNP (pmol/L) [<100 ] 
Creatinine (mg/dL) [0.6-1.2] 




















The groups were well matched at baseline for all characteristics (255). As previously reported 
(255) the T2* improved in both the combined therapy groups (desferioxamine and deferiprone) 
and the desferioxamine and placebo group (placebo group). The T2* increased significantly 
more in the combined therapy group 11.7ms at baseline to 17.7ms at 12 months (P<0.001) 
versus 12.4 ms at baseline to 15.7ms at 12 months (P=0.001) in the placebo group. The between 
group difference was significantly in favour of the combined treatment group with an estimate 
of a 10% increase in the combined group compared with the desferioxamine only group (95% 
CI 2 to 19%, P=0.02).  
6.8.2. Standard Echo Data 
Looking at the echo parameters in the combined therapy (desferioxamine and deferiprone) group 
there were some significant improvements in the mean values across the 12 month treatment 
period. The following improvements were found.   
1.) The 4 chamber EF increased from 60% to 63.9% at 12months, P=0.006 
2.) The M mode EF increased from 59.2% to 65.2% at 12 months, P=0.000  
3.) LV systolic diameter reduced from 3.3 cm to 3.1 cm at 12 months, P=0.007.  
There was no significant improvement in the mean left ventricular diastolic dimension or in the 
mean BNP levels which were 23.4 at baseline and 25.3 at 12 months P=0.602.  
When the corresponding parameters were analysed in the placebo group at 12 months, compared 
with baseline, the changes weren’t so marked. The mean M mode EF improved significantly 
from 59.2% to 61.6% but there was no significant improvement in the 4 chamber EF. The left 
ventricular diastolic dimension changed significantly but in an adverse direction, the LV getting 
bigger following 12 months of treatment. The left ventricular systolic dimension also increased 
although the difference was non significant. Again, the mean BNP values did not significantly 
change over the 12 months of treatment. 
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6.8.3. Tissue Doppler Data 
6.8.3.1 In The Treatment Arm 
When the tissue Doppler data was compared for the group receiving combined therapy at 12 
months compared with baseline, only the following significant changes were seen. 
1.) Basal Septum Aa increased from -4.5 to -5.1 cm/s, P=0.021.  
2.) Mid Septum Aa increased from -2.9 to -3.4 cm/s, P=0.005.  
3.) Basal Lateral wall Sa increased from 5.6 to 6.8 cm/s, P=0.032.  
Basal Lateral wall Aa increased from -3.8 to -4.9 cm/s, P=0.021.  
4.) Mid Lateral wall Sa increased from 4.6 to 5.8cm/s, P=0.008.  
Mid Lateral wall Aa from -2.6 to -4.6 cm/s, P=0.030. 
Mid Lateral wall TT increased from 5.5 to 7.1cm/s, P=0.016.  
5.) Basal RV wall Aa increased  from -9.6 -10.6 cm/s, P=0.043.  
6.) Mid RV wall Sa increased from 7.3 to 8.3 cm/s, P=0.05. 
Mid RV wall Aa increased from -5.2 to -8.1 cm/s, P=0.000. 
Mid RV wall TT increased from 12.2 to 14.8 mm, P=0.04. 
The remaining parameters showed no significant improvement after 12 months of combined 
chelation therapy. 
 
6.8.3.2 In The Placebo Arm 
In the trial placebo group the following significant improvements were seen when comparing 
baseline to 12 months therapy. 
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1.) Basal Septum Sa increased from 5.0 to 5.5 cm/s, P=0.010 
Basal Septum TT increased from 8.9 to 9.9 mm, P=0.011.  
2.) Mid Septum TT increased from 5.6 to 7.1 mm, P=0.028.  
3.) Basal Lateral wall Sa increased from 5.4 to 6.1 cm/s, P=0.042.  
Basal Lateral wall Ea increased from -10.3 to -11.7 cm/s, P=0.005 
Basal Lateral wall Aa increased from -3.5 to -4.3 cm/s, P=0.006.  
Basal Lateral wall TT increased from 8.6 to 10.3 mm, P=0.000 
4.) Mid Lateral wall Aa increased from -2.4 to -3.3 cm/s, P=0.008.  
5.) Basal RV wall Sa increased  from 10.7 to 11.6 cm/s, P=0.013.  
Basal RV wall TT increased from 19.5 to 21.9 mm, P=0.016 
6.) Mid RV wall Sa increased from 6.7 to 8.3 cm/s, P=0.001. 
Mid RV wall Ea increased from -6.6 to -7.6 cm/s, P=0.031. 
Mid RV wall Aa increased from -5.7 to -7.0 cm/s, P=0.036. 
Mid RV wall TT increased from 10.5 to 13.6 mm, P=0.001. 
 
The remaining parameters showed no significant improvement after 12 months of treatment. 
Although there were a number of parameters that improved significantly after 12 months 
combination therapy only late diastolic velocity (Aa) improved in all regions analysed. In the 
placebo group there were also a number of significant improvements, frequently in the 




CHAPTER 7: CONCLUSIONS & DISCUSSIONS 
 
7.1 OVERALL STUDY POPULATION  
The 167 patients screened were divided by T2* categories. 108 patients (65%) had a T2* <20ms 
indicating significant cardiac iron. Of these 22 (13% of total screened) had severe cardiac iron, 
i.e. T2*<8ms. The remaining 59 had T2*>20ms indicating no clinically significant cardiac iron. 
The proportion of the screened group with cardiac iron, i.e. a T2* <20ms was higher than 
expected compared with other reported series. The predicted number screened of 167 was 
calculated to identify the required number of patients with mild to moderate cardiac iron 
loading. This was based on an anticipated 40% of screened patients who were maintained on 
desferioxamine having mild to moderate cardiac iron loading (T2* 8-20ms) and therefore being 
eligible for the trial. Other studies have found varying degrees of cardiac iron involvement in 
those at risk, 16% in a retrospective study looking at costs of care (256) & 10% in a study by 
Cunningham (257). A study from Pakistan found 59% of patients had one or more cardiac 
abnormality including 23% with systolic dysfunction and 29% with diastolic dysfunction (258). 
Vichinsky found a 20% rate of cardiac disease in thalassaemia (259) patients undertaking 
regular blood transfusions and an epidemiological study from Germany published in 2000 found 
a rate of 13 % for cardiac siderosis and complications (260) in treated thalassaemics between the 
ages of 9 and 15. Overall in our group there was a high ratio of significant cardiac iron loading. 
It is unclear why such high rates were found. These patients were all cared for by haematologists 
and were receiving the best available therapy. Many possibilities could account for why such 
high proportions of cardiac iron were found. These include poor uptake of chelation treatment, 
inadequate desferioxamine dosing, poor compliance with chelation therapy, poor access to 
specialists with an interest in assessing cardiac status, poor availability of techniques for 
imaging cardiac status, lack of availability / cost of Deferiprone. Ultimately, in our study group, 
 113
it is not clear which of these factors have contributed to the relatively high proportion of patients 
with significant cardiac iron overload, although the causes are likely to be multifactorial. 
 
7.2 BRAIN NATRIURETIC PEPTIDE 
Overall measuring brain natriuretic peptide values did not help us to stratify an individual 
patients risk for cardiac iron overload or of developing cardiac failure. Those with BNP levels 
greater than 100 all had significant cardiac iron and therefore levels above this threshold should 
indicate the need for urgent cardiac evaluation with MRI and TTE and optimisation of chelation 
therapy. However, of those with severe cardiac iron (T2*<8ms), only 2 patients had a BNP of 
>100pg/ml. Indeed, of the 22 patients with T2* <8ms, 6 had a BNP level of <20 pg/ml and 1 
patient had a BNP level of <5pg/ml. These findings are consistent with other groups who have 
looked into the role of BNP in assessing cardiac iron. A group from Turkey found that BNP 
levels were normal in a group of patients with abnormal myocardial performance index 
calculated using pulsed tissue Doppler imaging (261). A group from Athens looked at the 
relationship between BNP and the evaluation and management of thalassaemia heart disease. 
They divided the group into those with NYHA class 3/4 symptoms (group A) those with class 2 
symptoms and EF <55% (group B) and those with normal systolic function, group C. They 
found that those in group A had significantly higher BNP levels than those in group B & C. 
However there were no significant differences in BNP levels between those in groups B & C 
(262). They conclude that BNP may have limited clinical usefulness in the thalassaemia 
population. Our results reach a similar conclusion (253). In our study those with severe cardiac 
iron loading, T2* of < 8ms had a trend towards higher mean BNP levels (72.6 +/- 35.7 pg/ml) 
than those with no cardiac iron, T2*>20ms (BNP 15.1 +/- 2.2 pg/ml). However the mean BNP 
levels were not statistically different and in the severe iron group the mean value was heavily 
influenced by a few outliers. Again we found no significant difference in mean BNP levels 
between those with mild – moderate cardiac iron levels (29.0 +/- 6.6 pg/ml) and those with no 
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iron. Overall, the BNP measurement in this cohort was redundant as it was only significantly 
elevated in those who had clinically evident heart failure and as such added nothing additional.  
 
In a study evaluating the role of N terminal pro BNP, a Greek group compared NT pro BNP 
levels and E/E’ (a marker of diastolic function) in 52 patients with transfusion dependent 
thalassaemia major with normal LV systolic function and 52 age matched controls. They found 
that NT BNP and E/E’ were increased in thalassaemia patients and were well correlated. They 
concluded that NT pro BNP increases in thalassaemia patients and is related to age and diastolic 
function (263). A Turkish group studied the relationship between NT pro BNP and ventricular 
function assessed by tissue Doppler velocities in thalassaemia patients compared to age matched 
healthy individuals. They found that NT pro BNP had an inverse correlation with LV and RV 
systolic velocities which were reduced compared with the healthy controls (264). 
We had aimed to explore whether changes from baseline BNP following scheduled blood 
transfusion could help to stratify which patients had significant cardiac iron loading and were at 
risk for cardiac failure. Our provisional results were encouraging, in a patient with no cardiac 
iron and BNP levels pre transfusion of 19.4pg/ml the BNP level immediately post blood 
transfusion remained static at 18.1 pg/ml. The BNP level was checked for 5 half lives and 
remained fairly constant at 25.3 pg/ml, 20.5 pg/ml, 20.6 pg/ml, 24.7 pg/ml and 21.1pg/ml. In 
contrast, in another patient with significant cardiac iron loading and a pre transfusion BNP of 
438 pg/ml, the BNP level increased by over 25% to a post transfusion level of 585 pg/ml. This 
level decreased to 394 pg/ml after 24 hours, comparable to the pre transfusion level. A high 
proportion of our patient cohort had travelled long distances across Sardinia to attend for the 
study in Cagliari and their routine transfusions were conducted at their local haematology 
clinics. For those who were local, chance dictated whether their transfusion happened to occur 
on the day when they were attending for study follow up. For those with transfusions scheduled 
during our visits some were reluctant to have yet more additional blood tests over a 2 hour 
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period and the following day. These factors meant we were unable to recruit many patients for 
this section of the study and in particular, unfortunately we were unable to assess any of the 
patients with cardiac iron present but normal BNP levels at rest to see how their BNP level 
responded with the challenge of blood transfusion. If despite the normal BNP level at rest, there 
was subtle LV dysfunction secondary to cardiac iron loading then it may be possible to detect an 
increase in BNP levels following a blood transfusion compared to those with no cardiac iron and 
normal BNP levels which remained fairly static as described above. This line of investigation 
with BNP may prove useful at identifying those with cardiac iron who are at risk of 
decompensation, although further work is required 
 
7.3 STANDARD ECHO DATA 
Worldwide, echocardiography forms the mainstay of evaluation for cardiac involvement in 
thalassaemia patients. However, it has long been recognised that ejection fraction calculated 
from transthoracic echocardiography is a poor indicator of cardiac iron loading and that 
reduction in ejection fraction occurs late in the disease process and conveys a poor prognosis. 
With the advent of cardiac MRI and T2* assessment we now have a means of quantifying iron 
load in different organs and importantly now have an accurate way of assessing cardiac iron 
load, a parameter that previously eluded us. Previously serum ferritin of >2500 ucg/l and liver 
iron from biopsy of >15mg/gm dry weight were used as surrogate markers to identify those at 
high risk of cardiac complications, cardiac MRI has firmly established these techniques to be 
inaccurate (75). The frequency of abnormalities detected on TTE is not well studied and little is 
known about their relationship with cardiac iron load. As early as 1978 a study demonstrated a 
high proportion of echo abnormalities in those at risk of myocardial iron deposition (121). They 
identified normal ejection fraction in all but 4 of the patients studied, all four however died 
within a six month period, suggesting that deterioration in systolic function occurs too late to be 
a useful means for risk stratification (121). We demonstrated a high frequency of abnormalities 
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on TTE evaluation. However, with the exception of reduced left ventricular function (EF<55%) 
which had a positive predictive value of 90% for cardiac iron and mild or moderate MR or TR 
with a positive predictive value of 80% the other parameters analysed had poor ability in 
predicting cardiac iron load. There have not been any previous studies documenting the 
frequency of valve lesions and its predictive value in identifying cardiac iron. In this study valve 
lesions were graded by visual assessment which is subject to observer variation and error. 
Further investigation in this area with more quantitative valve assessment including measuring 
PISA (proximal isovelocity surface area), vena contracta, regurgitant volume, regurgitant 
fraction and regurgitant jet area may prove useful. 
 
 
7.4 COMPARISON BETWEEN EJECTION FRACTION FROM TTE & FROM CARDIAC MRI 
The present study has demonstrated a good correlation between ejection fraction calculated from 
TTE and cardiac MRI. The strongest correlation between echo EF and MRI EF was obtained 
from the M mode measurements with a significant correlation of 0.736 with P=0.000. This is the 
first study comparing different methods for calculating ejection fraction in a thalassaemia 
population. There have been a number of studies comparing the ejection fraction calculated from 
echo and cardiac magnetic resonance imaging in other populations. There have been conflicting 
results. Some studies have demonstrated poor correlation and propose cardiac MRI to be the 
superior technique given its 3D volume assessment for ejection fraction calculation with 
superior image quality (265). Cardiac MRI is not subject to some of the limitations of TTE such 
as poor echo windows & suboptimal image quality, that often precludes the use of Simpsons 
biplane volume and ejection fraction assessment and the use of regional estimates to calculate 
global function (M mode EF calculation) are known to be limited. In a study of heart failure 
patients, ejection fraction from TTE, cardiac MRI and radionuclide ventriculography were 
compared. There was poor correlation between the techniques. The strongest relationship was 
 117
between cardiac MRI and 2d echo Simpson’s biplane assessment. This is unsurprising given that 
both methods calculate ejection fraction using a similar principle (summation of slice areas). 
However in the TTE group 30% had image quality that was too poor to use the Simpson 
technique (265). Further work by the same group evaluated the use of different techniques for 
assessing cardiac function in a 1 stop clinic for heart failure patients. It is important to note that 
this was not performed in thalassaemia patients who by merit of their slim builds tend to be 
more echogenic than in the general adult population. They found only a limited correlation 
between CMR and echo with a correlation coefficient of 0.6, which is lower than the values we 
obtained (266). Cardiac MR was acceptable to patients but the scanning time was almost twice 
as much as for echo (266). However the good reproducibility lends itself to longitudinal studies 
of progression and treatment in patients with heart failure (266). Other studies have 
demonstrated a good correlation particularly when intravenous contrast is used to enhance echo 
endocardial border definition (267). In their study, Skjaerpe et al found 23 patients had a 
difference in EF of > or = to 10% between non contrast echo and cardiac MRI calculation and 
this figure decreased to 0 after the addition of intravenous contrast to reassess echo EF. The 
same group have demonstrated further improvements in correlation by using apical long axis 
rather than apical 2 chamber in addition to the 4 chamber view for Simpson’s calculation (268). 
Ultimately what limits the reliability of EF from TTE is related to the inherent limitations of 
echo as a technique, mainly poor endocardial definition, which can to a degree be overcome 
with the use of intravenous contrast agents to opacity the left ventricular cavity and poor echo 
windows, inherent to the individual patient that are more difficult to overcome.  
In our study the correlation demonstrated was much better; likely because of a small number of 
operators and that generally thalassaemia patients are good subjects for transthoracic 
echocardiography. For practical purposes EF from TTE gives a good indication of cardiac 
function and an EF of < 50% gives a high likelihood of significant cardiac iron loading. 
 
 118
7.5 DIASTOLIC ECHO DATA 
We did not find a significant relationship between transmitral E:A ratio and cardiac iron from 
T2*. It is recognised that the transmitral E:A ratio is a poor measure of diastolic function as it is 
heavily influenced by loading conditions. Thalassaemia patients will have different loading 
conditions dependent on where they are in their transfusion cycle, so it is perhaps not surprising 
that we did not observe a relationship. We also looked at e wave deceleration times and again 
this did not correlate with the severity of cardiac iron loading, the mean times being similar in 
the group with no cardiac iron compared to the group with severe cardiac iron. We did not 
assess some of the other conventional markers of diastolic function such as pulmonary vein flow 
profile and isovolumetric relaxation period. It is well recognised that these assessments of 
diastolic function are influenced by loading conditions and therefore may not be as useful in 
thalassaemia patients where the loading conditions are highly variable from day to day and are 
influenced by blood transfusions. Overall, the standard Doppler measures of diastolic function 
were not useful. 
 
7.6 SYSTOLIC FUNCTION FROM MYOCARDIAL TISSUE DOPPLER VELOCITIES 
There is a fairly limited evidence base for the use of tissue Doppler techniques to assess patients 
with thalassaemia. Our group in 2003 published the first work indicating the role of tissue 
Doppler velocities (183). Vogel’s study identified 38 patients with abnormal iron loading of the 
myocardium and 33 of these had regional wall motion abnormalities identified by abnormal 
myocardial systolic velocities. In 29 out of 33 patients the abnormalities were in the septum. In 
this study we demonstrated significantly lower mean systolic velocities in the group with severe 
cardiac iron load than those with no cardiac iron in the basal and mid sections of both the 
septum and RV free wall. The systolic velocities in the lateral wall were not significantly 
different across the cardiac iron severity groups. The septum is the main location for iron 
deposition and can help explain the impaired systolic velocities. It is of note that the RV wall 
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had significant reduction in systolic velocities suggesting that iron deposition in the right 
ventricle may be more substantial than previously thought. Lateral wall function and velocities 
appeared least affected by cardiac iron. In a study of normal subjects the systolic velocities in 
the basal septum were 6.7 +/- 1.4cm/s and in the basal lateral wall 6.7 +/- 1.5cm/s (269). This 
compares with our group without cardiac iron where the mean basal septum values were lower 
at 5.7 +/- 1.18cm/s and similar in the basal lateral wall at 6.4 +/- 1.7cm/s. A group from Turkey 
showed significant decreases in the peak systolic velocity in both the LV and RV in patients 
with thalassaemia compared with controls (264). An Italian group looked at tissue Doppler 
velocities in an asymptomatic group of patients with thalassaemia and compared them with 
controls. They found significantly lower myocardial systolic tissue Doppler velocities in the 
basal LV, septum and RV walls (270). Hamdy’s group found lower myocardial systolic 
velocities in the basal lateral wall but not the basal septum or basal RV wall in thalassaemia 
patients compared to controls (271).  
Our findings are in keeping with those from other studies, indicating reduced systolic velocities 
in those with thalassaemia compared to the values obtained from normal subjects. In our study 
the thalassaemia group without iron can be thought of as the control group and we demonstrated 
significantly lower systolic velocities in the septum and RV walls in the group with significant 
cardiac iron. Further work will be required to determine the best region to analyse, although in 
studies to date the septum appears to be consistently involved, which given the septum is the 
main location for iron deposition, is perhaps no surprise. Obtaining TDI data for systolic 
velocities is less user and image dependent than conventional EF estimation, making this 






7.7 DIASTOLIC FUNCTION FROM TISSUE DOPPLER MEASURES 
Studies have correlated the E/Ea ratio with PCWP (pulmonary capillary wedge pressure) and 
found that a PCWP of greater than 15mmhg can be predicted from an E/Ea ratio of greater than 
11 in patients with preserved LVEF and of greater than 15 in patients with impaired LV systolic 
function (272). Other groups have also demonstrated good correlation between E/Ea ratio and 
LVEDP and PCWP (273). In a review article by Dokainish, it is concluded that an E/Ea of <10 
indicates normal left ventricular filling pressures, while an E/Ea of >15 indicates elevated left 
ventricular pressures. A ratio of between 11-14 is in a grey zone where other variables such as 
left atrial volume, pulmonary venous flow profile and brain natriuretic peptide levels should be 
taken into consideration (274;275). A group in India studied thalassaemia patients with normal 
systolic function and compared them with matched healthy controls. They found that the E/A 
ratio was the same between the groups but that in the thalassaemia group the E/Ea ratio, 
calculated from tissue Doppler velocities at the lateral mitral annulus, was higher than in the 
control group, although the mean values for the group were still <10 (9.46+/- 1.5) (276). They 
concluded that diastolic dysfunction preceded systolic dysfunction.  
Of interest in our study, the group with significant cardiac iron loading had significantly higher 
E/Ea ratios in the basal septum (14.9 +/- 4.5) than the group with no significant cardiac iron. 
This would suggest higher left ventricular filling pressures in the group with severe cardiac iron. 
This may be logical as the myocardium may become stiffer as the level of iron infiltration 
increases. However, also worth noting is that in the group with no cardiac iron where the mean 
EF from 4 chamber echo was normal at 63% the mean E/Ea ratio was 12.5 in the basal septum. 
This suggests that even in the group with no cardiac iron and normal ventricular function the 
diastolic function is abnormal with evidence of borderline elevated left ventricular filling 
pressures. While anaemia may contribute to some diastolic dysfunction the use of E/Ea ratio, 
which forms an index of volume load corrected to myocardial relaxation, attempts to account for 
differences in loading conditions. However it is also recognised that E/Ea ratio has a better 
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correlation with LV filling pressures in patients with depressed EF than in those with preserved 
EF (277). Also of note we demonstrated that in our study population the mean Aa velocity 
(myocardial velocity during atrial systole) was significantly lower in the group with severe 
cardiac iron loading than in group with T2*>20 ms. This finding was present in all regions 
except the mid RV. Hamdy’s group had also looked at Aa velocities and interestingly found 
significantly higher values in the basal septum and basal RV wall in thalassaemia patients 
compared to controls (271). This is in contrast to our findings as although we did not have a 
control group one could consider those with no cardiac iron and T2* greater than 20ms to 
represent our control group. A study in Greece by Aessopos’s group had identified patients 
whom developed systolic dysfunction and looked at earlier echocardiograms for predictive 
factors. They identified low values of diastolic A wave as a predictor for deteriorating LV 
function over 10 years (278). These diastolic changes are intriguing and it would be interesting 
to follow patients with abnormal E/Ea ratios across a period of time to see if they can predict 




An Italian group looked at strain imaging in an asymptomatic group of patients with 
thalassaemia and compared them with controls. They found significantly lower strain measures 
in the basal LV, septum and RV walls (270). Hamdy’s group found that their strain results 
matched their results for systolic velocities with a lower value of strain in the basal lateral LV 
wall compared to controls  (271). In our study we were unable to find any clear relationships 
between strain measured at any of the 3 time points and cardiac iron loading from T2*. Our 
strain curves were highly variable and this may have influenced the lack of clear relationships. 
Strain is influenced by pressure and volume and this may account for some of the variability 
(151). In some subjects we identified post systolic strain; a finding previously described in 
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studies looking at cardiac ischaemia and felt to be an early sign that represents the late 
asynchronous contraction that falls within the period of isovolumetric relaxation. Also called 
post systolic shortening, post systolic thickening or post systolic motion it has been associated 
with the presence of ischaemia and myocardial viability (279;280). Other studies have suggested 
a role for post systolic motion in identifying different substrates of infarction (transmural versus 
subendocardial) and different models of viability (stunned or hibernating) (281-283). It is not 
clear what post systolic strain represents in this population but in our study it did not relate to 
cardiac iron load severity. Studies of normal subjects vary in the values quoted for strain. These 
differences likely relate to different methodologies (PW versus colour TDI), different frame 
rates, placement of sample volumes in different regions and different values for different walls. 
Normal longitudinal strain is quoted from -10 to -15% (151) to -9 to -30% (269). In our baseline 
cohort the strain values were consistent with those published for normals except from the basal 
lateral wall which had low strain values even in the group without significant iron.  
The studies examining strain, including our own, have yielded mixed results so far and without 
any clear relationship at this stage, strain does not appear to have a role in the assessment of 
patients with transfusion dependent thalassaemia.  
  
7.9 STRAIN RATE 
Ours is the first study to date to examine strain rate in thalassaemia patients. Strain is a measure 
of tissue deformation and is defined as the change in length normalized to the original length. 
The rate or speed at which this change occurs is called strain rate. In general, peak systolic strain 
rate is the parameter that comes closest to measuring local contractile function in clinical 
cardiology. It is relatively volume independent and is less pressure dependent than strain (151). 
Although the strain rate curves were less variable we did not demonstrate any relationship 
between strain rate and cardiac T2*. Normal values for strain rate are between -1 to -1.5 (151). 
The strain rate values in our cohort were consistent with those from a normal population except 
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for the lateral walls where the SR with severe iron was -0.64 +/- .5, no iron -0.87 +/- .9 and the 
mid lateral wall severe iron -0.62 +/- .5, no iron -0.81 +/- .5. It is not clear why the SR values 
were notably lower in the lateral wall especially given that the lateral wall systolic velocities 
were least affected by cardiac iron loading However, in another cardiomyopathy, that of Fabry’s 
disease, peak systolic strain and strain rate have shown improvement following enzymatic 
substitution therapy (179). In its current form strain rate does not appear to have a role in the 
management of transfusion dependent thalassaemia patients. 
 
7.10 TISSUE TRACKING / LONGITUDINAL MOTION  
There are no other studies looking at longitudinal displacement as a measure of cardiac iron load 
or cardiac function in patients with transfusion dependent thalassaemia major. We found that the 
longitudinal motion was less in those with severe cardiac iron as compared to those with no 
cardiac iron in the basal and mid septum and RV walls. In the severe cohort who were treated at 
the discretion of the supervising haematologist the TT (longitudinal displacement) increased 
significantly across the 12 month treatment period in the mid walls of the septum, lateral and 
RV free walls. 
 
7.11 TISSUE DOPPLER ECHOCARDIOGRAPHY IN LONGITUDINAL STUDIES 
The cohort with severe cardiac iron were excluded from randomisation and received best 
medical care at the discretion of their local haematologists. The myocardial T2* score improved 
significantly corresponding with significant de-ironing of the heart. The corresponding ejection 
fraction from echo also improved significantly. The systolic velocities in the septum and RV 
free wall improved significantly with de-ironing of the heart. In countries where cardiac T2* 
assessment is limited, systolic velocities in the septum and RV may prove very useful to risk 
stratify patients according to severity of cardiac iron loading and to track de-ironing of the heart 
following a period of intensive iron chelation therapy. Ea in the mid septum and basal lateral 
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walls, Aa in the basal lateral, mid lateral and mid RV walls and TT in the mid septum and mid 
RV walls are significantly reduced in those with severe cardiac iron compared to those with no 
cardiac iron and the values increase significantly after a period of intensive chelation. These 
parameters may be helpful in identifying those with severe cardiac iron and monitoring their 
improvement following intensive iron chelation therapy. 
 
7.12 RANDOMISED COHORT 
The combined group had a significantly greater improvement in cardiac T2* score following 12 
months combined treatment. There was a corresponding increase in the echo M mode and 4 
chamber EF in addition to significant improvements in the LV systolic dimensions. This is in 
contrast to the placebo group where the mean M mode EF did show some improvement but was 
not significant and there was no real change in 4chamber EF. The LV diastolic dimensions 
increased over the 12 months of treatment. When comparing the tissue Doppler data only the 
late diastolic Aa velocity significantly improved over the 12 month period. This improvement 
was seen in all the 6 different regions. It is not clear why the Aa velocities improved in our 
cohort as the heart is deironed. It is perhaps suggestive of iron in the atrial walls causing reduced 
atrial systolic force and contraction and hence a reduced Aa velocity. As the iron is removed 
from the atrial walls the atrial function can improve and the atrial systolic velocities increase. 
 
7.13 WHY ECHO IS AN IDEAL TOOL FOR ASSESSMENT 
Whilst our study has not demonstrated a clear role for these new echo techniques in the 
management of transfusion dependent thalassaemia patients it has demonstrated some useful 
conclusions. Particularly with respect to assessing the likelihood of severe versus no cardiac 
iron, some of the tissue Doppler systolic indices, diastolic indices and tissue tracking / 
longitudinal motion values can be very useful. Echocardiography itself remains a hugely useful 
tool for these patients, it is portable, easily available and clinicians are familiar with the 
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information it gives. Whilst none of the traditional or newer echo techniques can be used to 
ultimately determine an individuals cardiac iron load (for which cardiac T2* MRI would be 
required), a number of the newer parameters can give a very useful likelihood of significant 
cardiac iron loading and be useful to assess which patients should be referred for cardiac MRI 
T2* evaluation. Sequential changes in some of these newer echo techniques can also be used as 
surrogate markers to determine which of those on intensive chelation regimens are responding 
well and which may need more urgent repeat T2* assessment. This may prove essential in areas 
where the availability of cardiac MRI is very limited and costly.  
Echocardiography remains an essential tool for assessing function and sequential change in 
function in this group of patients. We have demonstrated an excellent correlation between 
function derived by echo and that generated from the gold standard, cardiac MRI assessment. In 
the thalassaemia population some of the limitations of echo LV functional assessment are 
reduced by the inherent characteristics of the population, young, slim and usually no respiratory 
disease. This leads to improved endocardial definition and more accurate biplane Simpson’s 
ejection fraction estimation, whilst global rather than regional LV abnormalities improve the 
accuracy and reliability of M mode EF estimation. 
Whilst cardiac MRI remains the definitive technique for determining cardiac iron involvement 
in thalassaemia patients, transthoracic echocardiography will continue to provide the structural 
and functional information on a day to day basis and can provide immediate information for the 
clinician to help select which patients require T2* MRI assessment. It will remain essential for 
monitoring changes in cardiac status, function and treatments, in addition to being an essential 






7.14 LIMITATIONS OF THE STUDY 
The main limitation of this study is that we have not accounted for differences in preload related 
to different haemoglobin levels at the time of assessment and differences related to timing of the 
most recent blood transfusion. While this may appear to be an obvious source for error when 
comparing BNP and tissue Doppler values between patients, many studies in the literature make 
no mention of controlling for these differences (271;284;285). A few studies have attempted to 
mimimise these variations, for example by taking patient blood samples and performing 
echocardiography at the end of the week prior to blood transfusion (286). However, this still 
allows for a variation of between 3 and 7 days before the next transfusion. Another group 
sampled NT pro BNP on the 3rd day following blood transfusion (287). This is perhaps a better 
method for standardisation, but, as with all the above studies, there is no mention of adjustment 
for different pre-transfusion haemoglobin levels. What is clear from the literature is that there 
are no clearly accepted methods to account for these important sources for variation in results. 
Having not controlled for different haemoglobin levels and timimgs of transfuions may in part 
explain why we failed to document significant differences in some of the measured parameters 
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